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Abstract: 21 
Purpose: Compound solubility serves as a surrogate indicator of oral biopharmaceutical performance. 22 
Between infancy and adulthood, marked compositional changes in gastrointestinal (GI) fluids occur. This 23 
study serves to assess how developmental changes in GI fluid composition affects compound solubility. 24 
Methods: Solubility assessments were conducted in vitro using biorelevant media reflective of age-25 
specific pediatric cohorts (i.e. neonates and infants). Previously published adult media (i.e. FaSSGF, 26 
FeSSGF, FaSSIF.v2, and FeSSIF.v2) were employed as references for pediatric media development. 27 
Investigations assessing age-specific changes in GI fluid parameters (i.e. pepsin, bile acids, pH, 28 
osmolality, etc.) were collected from the literature and served to define the composition of neonatal 29 
and infant media. Solubility assessments at 37oC were conducted for seven BCS Class II compounds 30 
within the developed pediatric and reference adult media.  31 
Results: For six of the seven compounds investigated, solubility fell outside an 80-125% range from adult 32 
values in at least one of the developed pediatric media. This result indicates a potential for age-related 33 
alterations in oral drug performance, especially for compounds whose absorption is delimited by 34 
solubility (i.e. BCS Class II). 35 
Conclusion:  Developmental changes in GI fluid composition can result in relevant discrepancies in 36 
luminal compound solubility between children and adults. 37 
 38 
 39 
 40 
 41 
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Abbreviations: 42 
 43 
IVIVC – in vitro – in vivo correlations 44 
GI – gastrointestinal 45 
P-BCS – pediatric biopharmaceutics classification systems 46 
BCS - biopharmaceutics classification systems 47 
FaSSGF- fasted-state simulated gastric fluid 48 
FeSSGF- fed-state simulated gastric fluid 49 
FaSSIF- fasted-state simulated intestinal fluid 50 
FeSSIF- fed-state simulated intestinal fluid 51 
US-FDA - United States Food and Drug Administration 52 
NaTc – sodium taurocholate 53 
PNA – postnatal age 54 
GA – gestational age 55 
NEC – necrotizing enterocolitis 56 
FFA – free fatty acids 57 
 58 
  59 
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Introduction: 60 
The use of in vitro tests to forecast oral drug performance can serve to identify compounds 61 
displaying inadequate or unfavorable absorption profiles during early stages of drug development. To 62 
facilitate such in vitro – in vivo correlations (IVIVC), test media utilized should reflect the complex 63 
physiochemical nature of human gastrointestinal (GI) fluids.  Accordingly, several formulas of biorelevant 64 
media have been developed based on the intraluminal conditions of the GI tract in adults (1-3). For 65 
immediate release dosage forms, where drug release is expected to occur within the upper region of the 66 
GI tract, biorelevant media depicting the stomach and proximal small intestine are typically formulated.   67 
Compared to compendial media, use of biorelevant media within in vitro dissolution experiments 68 
has been demonstrated to provide IVIVC that better predict oral drug absorption in adults (4, 5). Despite 69 
these favorable results, the use of biorelevant media for establishing IVIVC within pediatric populations is 70 
contentious. This is because contemporary biorelevant media (1, 2) are formulated based on 71 
gastrointestinal conditions of an adult human. Consequently, their applicability towards pediatric 72 
populations, who are developmentally distinct in terms of gastrointestinal anatomy/physiology, remains 73 
questionable. Of most interest are children belonging to the youngest age groups (i.e. neonates and 74 
infants) who display the greatest developmental differences in comparison to adults (6, 7). 75 
In recognition of the potential impact that developmental differences in GI anatomy/physiology 76 
can exert on oral drug absorption, a Pediatric Biopharmaceutics Classification System (P-BCS) Working 77 
Group was assembled to assess whether a similar classification system as utilized in adults could be 78 
developed for children (8). The Biopharmaceutics Classification System (BCS) categorizes drugs based on 79 
two properties, aqueous solubility and permeability (9). Accordingly, compounds can be classified as 80 
either BCS I (high solubility, high permeability), II (low solubility, high permeability), III (high solubility, low 81 
permeability), or IV (low solubility, low permeability). The classification system supports several aspects 82 
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of oral drug development in adults, including assessment of generic biowaiver applicability, lead 83 
compound selection, and formulation development (8). Based on their findings in a 2012 publication, the 84 
P-BCS Working Group concluded that in order to have merit, substantial knowledge gaps with regards to 85 
pediatric GI physiology, intestinal permeability, and ontogeny of drug metabolizing enzymes/transporters 86 
needs to be addressed prior to establishing of a pediatric-focused BCS (8). To enhance its applicability 87 
towards pediatric populations, it is clear that development of a P-BCS would require considerable 88 
modification of the current system. Of interest is how developmental changes in GI fluid composition 89 
affects compound solubility in relation to adults. 90 
In addition to age-related changes, the composition of GI luminal fluids undergoes positional 91 
changes from the stomach to the colon. Changes in composition including bile salt concentration, pH, 92 
osmolality, buffer capacity, and presence of fat digestion products, can impart changes in compound 93 
specific solubility (10). Therefore, to discern whether relevant differences in luminal solubility exist 94 
between pediatrics and adults, quantification of the relationship between age and GI fluid composition is 95 
inherently required.  96 
This study serves to assess the impacts of growth and maturation on gastrointestinal solubility. 97 
Pediatric biorelevant media representative of the stomach and proximal small intestine were developed 98 
based on an assessment of the available literature. Developed pediatric media were utilized to perform 99 
solubility assessments for seven BCS Class II compounds. To assess the impact of developmental changes 100 
in fluid composition, solubility values were compared between the different age-specific media including 101 
media representative of adults. 102 
Methods: 103 
(i)Materials: 104 
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Acetic acid (>99.7%), acetonitrile, dapsone, fenofibrate, indomethacin, hydrochloric acid 36.5-105 
38%, methanol, pepsin (from porcine), phenytoin acid and sodium oleate were obtained from Sigma-106 
Aldrich Company Ltd., Dorset, England. Griseofulvin, maleic acid, sodium acetate, sodium chloride, sodium 107 
hydroxide, orthophosphoric acid and spironolactone were acquired from Fisher Scientific UK Ltd., 108 
Loughborough, England. Ammonium acetate (FSA Laboratory Supplies, Loughborough, UK), 109 
carbamazepine (Fagron UK Ltd, Newcastle upon Tyne, England), sodium taurocholate (Prodotti Chimici 110 
Alimentari S.P.A., Basaluzzo, Italy), egg lecithin - Lipoid EPCS (Lipoid GmbH, Ludwigshafen, Germany) and 111 
glyceryl monooleate - Rylo Mg 19 (Danisco, Brabrand, Denmark) were obtained from the sources 112 
specified. Ultra-high-temperature treated whole cow’s milk standardized to less than 4% fat was acquired 113 
from Sainsbury’s, London, England. Two infant formulas manufactured by Cow & Gate, Trowbridge, 114 
England were utilized in the study: First Infant Milk (cow’s milk-based formula) and Infasoy (soya-based 115 
formula). Water was ultra-pure (Milli-Q) laboratory grade. Dialysis tubing (12-14000 Da MWCO) was 116 
acquired from Medicell Membranes Ltd., London, England.  Equipment utilized in the current investigation 117 
included a Buchi R114 Rotavapor (Flawil, Switzerland), a Beckman Coulter J2-MC centrifuge (High 118 
Wycombe, England), a Mettler Toledo SevenCompact S210 pH meter (Schwerzenbach, Switzerland), an 119 
Advanced Instruments Inc. micro-osmometer Model 3300 (Norwood, MA) and an Agilent Technologies 120 
1200 series HPLC system (Santa Clara, CA): binary pump (G1212A), autosampler (G1329A), thermostatted 121 
column compartment (G1316A), and diode array detector (G1315D). 122 
 123 
(ii)Media development: 124 
Biorelevant media as characterized by Jantratid et al. (2)  were selected as the focal points from 125 
which subsequent age-specific media were developed. The authors described four separate media 126 
reflective of the physiology of the stomach and proximal small intestine in adults in fasting and fed states: 127 
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Fasted-State Simulated Gastric Fluid (FaSSGF), Fed-State Simulated Gastric Fluid (FeSSGF), Fasted-State 128 
Simulated Intestinal Fluid v2 (FaSSIF.v2), and Fed-State Simulated Intestinal Fluid v2 (FeSSIF.v2) (Table I).  129 
Based on relative differences between adult and pediatric GI physiology, components of the reference 130 
adult media were modified to generate age-specific media.  131 
Investigations assessing developmental changes in gastrointestinal fluid composition were collected 132 
from the literature. For studies where information was displayed graphically, data was quantified using 133 
GetData Graph Digitizer (v2.26). Dependent on the specific media being formulated (i.e. FaSSGF), 134 
information pertaining to different physiological parameters were required: 135 
(a) FaSSGF – pepsin concentrations, pH, osmolality, and bile salt/lecithin concentrations 136 
(b) FeSSGF – feed type(i.e. cow’s milk-based vs. soy-based formula), pH, osmolality, and buffering 137 
capacity  138 
(c) FaSSIF – pH, bile salt/lecithin concentrations, osmolality, and buffering capacity 139 
(d) FeSSIF – pH, osmolality, bile salt/lecithin concentrations, fat digestion products, and buffering 140 
capacity 141 
Parameters values were compiled and, where suitable, graphically displayed as a function of age as 142 
an initial evaluation. If changes in GI fluid parameters between pediatric age groups and adults were 143 
noted, differences were computed based on a simplistic measure, the arithmetic mean. As the propensity 144 
of developmental effects were expected to be most prominent within the earliest stages of life, media 145 
reflective of the following age groups were formulated: neonates (0 – 28 days) and infants (1 – 12 months). 146 
When data pertaining to specific parameters were unavailable in children, either a default value 147 
representative of adult media or an inference based on current physiological knowledge was adopted. 148 
Based on this analysis, biorelevant media reflective of pediatric physiology were defined. Media 149 
preparation was conducted using the methods depicted in Jantratid et al (2). Measures of osmolality and 150 
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pH were instituted to ensure prepared media conformed to desired values. Osmolality was measured 151 
using freezing point depression (Micro-osmometer - Advanced Instruments Inc.).  Discrepancies between 152 
measured and desired osmolality were corrected by adjusting media sodium chloride concentrations as 153 
described in the literature (2). Media pH was titrated using 1M HCl or 1M NaOH, if necessary. Buffering 154 
capacity of pediatric formula (cow’s milk-based and soy-based) was determined based on the 155 
methodology presented by Hentges et al (11). Values presented represent the amount of acid or base (i.e. 156 
mEq) required to induce of pH change of 1 unit per litre of formula (12). 157 
 158 
 (iii)Solubility Assessments: 159 
(a) Compound Selection 160 
 Solubility assessments were conducted using BCS class II compounds. Compounds were further 161 
restricted to include only those with documented usages, including investigational uses, in both children 162 
and adults. Based on the above criteria, seven compounds were selected including carbamazepine, 163 
dapsone, fenofibrate, griseofulvin, indomethacin, phenytoin and spironolactone. Compound 164 
physicochemical properties are displayed in Table II. 165 
 166 
(b) Solubility Experiments 167 
Compound specific solubility assessments were conducted in each of the developed pediatric 168 
media as well as in the reference adult media to assess for age-related differences. Experiments were 169 
conducted within a shaking water bath set to 37OC and 200 strokes/min.  170 
Compound specific solubility values in aqueous-based media (FaSSGF, FaSSIF and FeSSIF) were 171 
determined based on the following procedure. A mass of solid (powdered) compound to saturate 10 mL 172 
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of biorelevant media was added to borosilicate glass tubes. Next, 10 mL of freshly prepared age-specific 173 
media (pediatric or adult) was added. Tubes were covered with parafilm and placed in the shaking water 174 
bath. Solubility assessments for all compounds, with the exception of fenofibrate, were conducted 175 
following a 24 hour dwell period. For fenofibrate, previous investigations have employed longer dwell 176 
periods (i.e. 48-72 hours) in order to achieve equilibrium solubility (13, 14). Correspondingly, a dwell 177 
period of 72 hours was utilized in this investigation. Saturated media samples were filtered through 0.45 178 
μm regenerated cellulose filters and diluted with fresh media prior to assessment. HPLC-UV was utilized 179 
to quantify solubility. Analytical HPLC procedures were based on modifications of methods depicted in 180 
the literature and are denoted in Table III. Solubility assessments were conducted in triplicate for each 181 
test media (pediatric and adult). Calibration curves were constructed using five standard concentrations. 182 
Standards were formulated as mobile phase dilutions of a concentrated stock solution consisting of 183 
compound dissolved in an organic solvent (i.e. methanol). All dilutions were conducted using volumetric 184 
glassware.   185 
Due to the addition of either milk or infant formula, fed-state gastric media exists as a complex 186 
multiphase system (15). Proteins within the media deter direct filtration of samples through 0.45 μm 187 
filters. As a result, the investigation utilized equilibrium dialysis to assess compound solubility within all 188 
fed-state gastric media, which negated the need for sample filtration to remove excess drug. To ensure 189 
restrictions in the rate of membrane permeation did not delimit solubility determinations, samples were 190 
permitted to dwell for an additional 24 hours compared to aqueous-based media. A mass of solid 191 
compound required to saturate 25 mL of media was added to separate 50 mL plastic centrifuge tubes. 192 
Twenty mL of freshly prepared media was then added. Next, a dialysis membrane (MWCO 12-14000 Da) 193 
containing 5 mL of fresh media was placed in each tube. Tubes were capped and placed in a shaking water 194 
bath. Solubility assessments were conducted after a 48 hour dwell period with the exception of 195 
fenofibrate, which was assessed after 96 hours. For assessment, tubes were taken from the water bath, 196 
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the dialysis membrane was removed, and its contents were extracted. One mL of media from the within 197 
the membrane was combined with 2 mL of methanol and vortexed for 5 seconds. The mixture was 198 
centrifuged at 8000 rpm and 4oC for 15 minutes. The resulting supernatant was filtered through 0.45 μm 199 
regenerated cellulose filters (Cronus) and diluted in mobile phase prior to analysis. Solubility values were 200 
quantified using HPLC-UV under the conditions specified in Table III. Calibrations curves with five standard 201 
concentrations were constructed for each test media. Standards were created by dilution of a stock 202 
solution, as described above, with fresh media using volumetric glassware. Solubility assessments were 203 
conducted in triplicate. 204 
One-way analysis of variance (ANOVA) with a post-hoc Tukey’s test was applied to identify 205 
statistically significant differences in solubility between various age-specific media (i.e. neonate-infant-206 
adult). All statistical analyses was conducted using R statistical software (v 3.1.2).  The investigation 207 
utilized a significance level of p≤0.05. Average solubility differences between developed pediatric media 208 
and the corresponding reference adult media were expressed as a ratio % (𝜇pediatric /𝜇adult x 100). Values 209 
greater than 100% indicate compound solubility within the pediatric media exceeded the solubility 210 
observed in adults, whereas values less than 100% conveyed the opposite. To denote relevant 211 
discrepancies in solubility, reference points corresponding to ratios of 80% and 125% were used. These 212 
values parallel the 80-125% bioequivalence criterion as specified by the US-Food and Drug Administration 213 
(US-FDA) (16). Within the analysis, statistically significant mean ratios falling outside the pre-specified 214 
boundary range were estimated to be at an increased risk for exhibiting alterations in oral drug 215 
performance between children and adults. In contrast, when mean ratios were within the 80-125%, 216 
boundary, age-specific solubility differences were not expected to alter oral drug performance.  217 
The influence of bile salts (NaTc) on modulating compound solubility within the developed 218 
biorelevant media was approximated using the equations presented by Mithani et al. (17), 219 
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𝑙𝑜𝑔𝑆𝑅 = 2.09 + (0.64 ∙ 𝑙𝑜𝑔𝑃) Eq.1 220 
𝑆𝐶𝑏𝑠 = 𝑆𝑅 ∙ 𝑆𝐶𝑎𝑞 Eq.2 221 
𝐶𝑠𝑥 = 𝐶𝑠𝑜 + (𝑆𝐶𝑏𝑠) ∙ (𝑀𝑊) ∙ ( [𝑁𝑎𝑇𝑐] )     Eq.3 222 
where SR is the solubilization ratio, logP is the logarithm of the octanol-water partition coefficient, SCbs is 223 
the bile salt solubilization capacity, SCaq is the solubilization capacity of water, Csx is the estimated 224 
compound solubility (mcg/mL) in the presence bile salts, Cso is the aqueous solubility (mcg/mL), MW is the 225 
compound specific molecular weight and [NaTc] is the media concentration (mM) of sodium taurocholate 226 
(bile salt). The equations, which describe the quantitative relationship between bile acids and compound 227 
solubility within aqueous based systems, incorporated bile salt concentrations for each age-specific media 228 
formulated with NaTc (FaSSGF, FaSSIF and FeSSIF). For neutral compounds (griseofulvin, spironolactone, 229 
carbamazepine and fenofibrate), experimentally determined aqueous solubility values served as inputs. 230 
For ionizable compounds (phenytoin-acid, indomethacin-acid, dapsone-base), pH specific aqueous 231 
solubility values, as estimated by the Henderson-Hassalbach equation, were utilized. The ratio of 232 
compound solubility, relative to adults, was estimated for each of the developed pediatric media (i.e. 233 
pediatricpred/adultpred x 100). A comparison between these predictions, which solely account for the effect 234 
of bile acids, and measured values, which account of the influence of all media components, was instituted 235 
using the root mean square error (RMSE). 236 
𝑅𝑀𝑆𝐸 = √
1
𝑛
∑ ((
𝜇 𝑝𝑒𝑑𝑖𝑎𝑡𝑟𝑖𝑐 𝑠𝑜𝑙𝑢𝑏𝑖𝑙𝑖𝑡𝑦(𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑) 
𝜇 𝑎𝑑𝑢𝑙𝑡 𝑠𝑜𝑙𝑢𝑏𝑖𝑙𝑖𝑡𝑦(𝑚𝑒𝑎𝑠𝑢𝑟𝑒𝑑)
𝑥100) −  (
𝑝𝑒𝑑𝑖𝑎𝑡𝑟𝑖𝑐 𝑠𝑜𝑙𝑢𝑏𝑖𝑙𝑖𝑡𝑦(𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑) 
𝑎𝑑𝑢𝑙𝑡 𝑠𝑜𝑙𝑢𝑏𝑖𝑙𝑖𝑡𝑦(𝑝𝑟𝑒𝑑𝑖𝑐𝑡𝑒𝑑)
𝑥100))
2
𝑛
𝑗=1  237 
Eq.4 238 
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Here, the RMSE provides a quantitative assessment of the influence of media bile salts on modulating 239 
compound solubility. For example, high agreement between predicted and measured solubility ratios, as 240 
indicated by lower RMSE values, infers NaTc is primarily responsible for observed solubility changes. 241 
Results: 242 
Literature data utilized to define age-specific GI parameters were primarily sequestered from studies 243 
examining healthy/normal children in order to mitigate the confounding effects of altered health statuses. 244 
For example, several investigations examining fasting gastric pH in children focused on pre-operative 245 
subjects with no known GI disease undergoing elective surgery. However, due the scarcity of pediatric 246 
data, some investigations examining critically ill subjects (i.e. NICU, PICU, or ICU patients) as well as 247 
preterm neonates were included in the analysis.  Such studies were additionally scrutinized to ensure their 248 
appropriateness towards defining GI parameters reflective of normal children. Assessments of gastric pH 249 
including critically ill subjects were restricted to studies where acid reducing agents (i.e. H2 antagonists) 250 
were withheld (18-20). Two pediatric studies assessing fasting gastric pepsin levels included subjects 251 
deemed as critically ill (21, 22).  As pepsin concentrations were presented as a percentage of adult values, 252 
data from these studies were compared to reference data (23) derived from critically ill adult subjects to 253 
normalize for any potential effects of illness. Similar to term neonates, preterm neonates by a gestational 254 
age of 34 weeks are expected to possess the ability to suckle and swallow to facilitate oral nutrition (24). 255 
Consequently, to minimize the effects of immaturity within the analysis, studies were delimited to those 256 
where the average postmenstrual age (gestational age + postnatal age) of subjects was approximately ≥ 257 
34 weeks. 258 
Pediatric Fasted-State Simulated Gastric Fluid (P-FaSSGF):  259 
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Studies depicting gastric pepsin concentrations in pediatric subjects are presented as a 260 
percentage of adult values in Figure1a.  Reported concentrations were measured in a fasting state with 261 
or without histalog stimulation. Values derived from histalog stimulation tests were compared to adult 262 
subjects referenced within the same study (25). For other studies, reference adult values were ascertained 263 
from separate investigations by the same research group or investigations utilizing a similar assay 264 
technique. A segmented analysis towards neonatal subjects  was only conducted in a single study (25). 265 
The investigation showed gastric pepsin concentrations approached infantile (1m-12m) levels after the 266 
first week of postnatal life. For example, neonates between 1-8 days postnatal age exhibited mean pepsin 267 
concentrations of ~15% of adult values while older neonates (10-32 days) and infants (67-110 days) both 268 
expressed similar mean concentrations of ~41% of adult values. Neonatal FaSSGF was developed based 269 
on the youngest cohort of subjects (i.e. those within the 1st week of life) to depict a state where the effects 270 
of development are most pronounced. Infant FaSSGF was formulated using pepsin concentrations 271 
summarized over several investigations. Concentrations of 15% and 25% of adult reference values 272 
(FaSSGF) were utilized for neonatal and infant FaSSGF, respectively.  273 
Investigations depicting fasting gastric pH values in pediatric subjects are summarized in Figure 274 
1b. Adult values represented by the mean from separate investigations, as summarized by Di Maio and 275 
Carrier (26), are displayed for reference. After the first day of life, fasting gastric pH rapidly normalizes 276 
towards adult values. Correspondingly, pediatric media (neonate and infant) representative of the fasted 277 
gastric state maintained the same pH as denoted by the reference adult media (i.e. FaSSGF - pH = 1.6).  278 
A single pediatric study was identified that investigated fasting gastric osmolality in 40 279 
postoperative infants with a mean age of approximately 8 months (27). The investigation depicted an 280 
average osmolality of 253 mOsm/L, which is more than twice the value of adult FaSSGF (120 mOsm/L). 281 
However, these finding may not be entirely reflective of healthy infants. In postoperative subjects, 282 
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administered medications and patient induced stress during surgery can effect gastric secretions and, 283 
thus, osmolality. Consequently, owing to the lack of appropriate data to establish a relationship between 284 
age and fasting gastric osmolality, the pre-established value from adults was employed to develop 285 
pediatric media. 286 
Literature-based assessments of gastric bile acids and phospholipids (i.e. lecithin) in the fasting 287 
state were not available for pediatric subjects. As the gastric mucosa does not contain the capacity to 288 
produce or excrete bile, the presence of gastric bile acids are primarily the result of duodenogastric reflux, 289 
a normal physiological phenomenon documented in adults (28, 29). Therefore, it was postulated that 290 
intestinal bile levels would influence the magnitude of bile acids present within gastric fluids. With 291 
frequent feeding schedules, neonates and infants are often maintained within the fed-state during waking 292 
hours. As such, bile acid (i.e. NaTc) values within pediatric FaSSGF were derived using fed-state intestinal 293 
bile levels. The following formula was used to quantify NaTc concentrations in pediatric FaSSGF, 294 
𝑝𝐹𝑎𝑆𝑆𝐺𝐹[𝑁𝑎𝑇𝑐] (𝑢𝑀) =  
𝑝𝐹𝑒𝑆𝑆𝐼𝐹[𝑁𝑎𝑇𝑐]
𝐹𝑒𝑆𝑆𝐼𝐹[𝑁𝑎𝑇𝑐]
∙ 𝐹𝑎𝑆𝑆𝐺𝐹[𝑁𝑎𝑇𝑐]    Eq.5 295 
where pFaSSGF[NaTc] is the bile acid (NaTc) concentration in pediatric FaSSGF, pFeSSIF[NaTc] is the NaTc 296 
concentration in pediatric FeSSIF, FeSSIF[NaTc] is the NaTC concentration in the reference adult FeSSIF 297 
media (10 mM), and FaSSGF[NaTc] is the NaTc concentration in reference adult FaSSGF media (80 uM). Bile 298 
acid values within pediatric FeSSIF media are presented in a forthcoming section.  For lecithin, pediatric 299 
FaSSGF was formulated to maintain the same ratio of [NaTc]/[lecithin] as depicted by adult FaSSGF. 300 
Compositions of the developed neonatal and infant FaSSGF media are presented in Table IV. 301 
Pediatric Fed-State Simulated Gastric Fluid (P-FeSSGF): 302 
The composition of FeSSGF is largely influenced by added meal components. In adult FeSSGF, 303 
cow’s milk is typically incorporated as it contains similar ratios of carbohydrate/protein/fat as a typical 304 
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breakfast meal and avoids logistic difficulties associated with the use of homogenized solid meals (30, 31). 305 
To institute the most physiologically relevant depiction of gastric contents in children, pediatric media 306 
were formulated using two types of commonly marketed infant formula: Cow & Gate First Infant Milk 307 
(cow’s milk-based formula) and Infasoy (soya-based formula).  Development of separate pediatric FeSSGF 308 
media comprised of different formulas permitted for forthcoming solubility assessments to investigate 309 
the influence of pediatric diet on biorelevant solubility. 310 
Gastric pH within the fed-state is dependent of several factors including feed composition and 311 
time of measurement (32, 33). Since many pediatric investigations administer various feeds (i.e. breast 312 
milk, infant formula, or D5W) and measure postprandial pH at selective time intervals, defining age-313 
specific pH values was quite challenging. Adult FeSSGF represents a snapshot of the ‘middle’ phase of 314 
gastric digestion between 75 and 165 minutes post-meal ingestion (2). The pH of adult FeSSGF was derived 315 
from Kalantzi et al.’s study, where a liquid meal consisting of 500mL Ensure plus® was administered to 20 316 
healthy subjects (33). The study denoted a pH of 5 as the approximate average over the abovementioned 317 
time period. However, in a separate investigation by Dressman et al. (34), where gastric pH was monitored  318 
following ingestion of a standard solid meal (1000 Kcal),  postprandial pH values differed from the results 319 
attained by Kalantzi et al. Following administration of a solid meal, gastric pH decreased towards fasting 320 
values at a faster rate compared to subjects administered a liquid meal. For example, median pH values 321 
persisted above 3 for approximately 60 minutes vs. > 180 minutes following solid meal vs. liquid meal 322 
ingestion, respectively (33, 34). As solid foods are anecdotally the most common form of meals consumed 323 
by adults, comparison of postprandial pH changes between children, administered a typical meal (i.e. 324 
formula), and adults, administered a solid meal, were used to define pH for the developed pediatric 325 
FeSSGF. Sondheimer et al. investigated the influence of postnatal age (PNA) on gastric pH in healthy 326 
preterm neonates (35). In-situ pH monitoring was conducted following administration of infant formula 327 
in two groups of neonates aged 2-6 days and 7-15 days PNA.  Comparing pH values at approximately 120 328 
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minutes post-meal (i.e, mid-point of the 75-165 minute time frame) between the cohort of older preterm 329 
neonates and adults, as reported by Dressman et al., pH was found to be higher (0.7-1.8 units) among 330 
neonates. As a result, neonatal FeSSGF was formulated to adopt a slightly higher pH (pH = 5.7) as 331 
compared to the reference adult FeSSGF (pH = 5). 332 
Osmolality of pediatric FeSSGF was defined by two investigations. The first, conducted by Billeaud 333 
et al. (36), characterized gastric osmolality among 15 low birth weight neonates with a mean PNA and 334 
gestational age (GA) of 8 days and 35.4 weeks, respectively. Eight test feeds, each differing in osmolality, 335 
were administered. The study noted a positive linear relationship between feed and gastric osmolality 336 
over the 3 hour study period. In a separate investigation by Thatrimontrichai and Janjindamai (37), three 337 
separate expressed breast milk feeds, which ranged in osmolality due to the addition of mineral/vitamin 338 
supplements, were tested in 26 neonate/infant subjects with a median PNA and GA of 30 days and 30 339 
weeks, respectively. Within the study, meals with higher osmolalities were found to be associated with 340 
comparatively higher gastric osmolalities over the 1 hour test period. A linear regression model depicting 341 
the degree of association between feed osmolality and 60 minute postprandial gastric osmolality was 342 
developed based on the results of Billeaud et al.’s (36) investigation (Figure 2). Although a 60 minute 343 
sampling point was not obtained during the original study, the value was estimated as the average 344 
between the 45 and 90 minute sampling intervals. The validity of the derived regression equation was 345 
tested by comparing gastric osmolality predictions to the data presented within Thatrimontrichai and 346 
Janjindamai’s study (37). The results of this comparison are depicted in Table V. Estimates from the 347 
regression equation were within 8% of measured values. As such, the equation was deemed appropriate 348 
for defining osmolality in neonatal FeSSGF. Although a sampling point of 60 minutes was clearly outside 349 
the time frame used to define adult FeSSGF (75-165 minutes), children, especially those within the 350 
youngest age groups, are typically fed on a more consistent basis during waking hours (i.e. every 2-3 351 
hours). Correspondingly, defining gastric osmolality in children based on one hour postprandial values 352 
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may provide an age appropriate representation of the ‘middle’ phase of gastric digestion, which adult 353 
FeSSGF is formulated to mimic. 354 
Since basal gastric volumes in infants are minute (38), the composition of gastric fluids 355 
postprandially can likely be attributed to the properties of the ingested meal. As such, the buffering 356 
capacity of pediatric FeSSGF was determined based on the buffering capacity of infant formula 357 
incorporated into the media. Since two separate neonatal media, one based on cow’s milk formula and 358 
the other based on soy formula, were developed, buffering capacity determinations for each respective 359 
formula were required. Determinations were conducted at pH 5.7, the desired pH of neonatal FeSSGF. 360 
The buffering capacity (mean ± SD) of cow’s milk formula at pH 5.7 was 14.03 ± 0.164. Soy-formula at pH 361 
5.7 displayed similar a buffering capacity (14.94 ± 0.318 mEq/L/∆pH). For simplicity, neonatal FeSSGF 362 
based on cow’s milk formula and soy formula media were prepared to target a buffering capacity 15 363 
mEq/L/∆pH. Compositions of the developed P-FeSSGF media are depicted in Table VI.   364 
Appropriate information to define infantile fed-state gastric fluids (i.e. 1-12m) was not attained 365 
from the literature. As a result, an infant FeSSGF media was not developed. However, as the composition 366 
of FeSSGF is primarily attributed the contents of the added meal component, assessments conducted in 367 
neonatal media which incorporate infant formula should provide a general indication of expected 368 
solubility changes in infants consuming similar feeds. In addition, comparisons between neonatal media 369 
that are similar in all respects with the exception of the type of meal component added (i.e. cow’s milk-370 
based formula vs. soy-based formula) provide an assessment of the impact of feed composition on 371 
biorelevant solubility. 372 
Pediatric Fasted-State Simulated Intestinal Fluid (P-FaSSIF):  373 
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 Intestinal pH values depicted in the literature are summarized as a function of postnatal age in 374 
Figure 3a. The majority of pediatric data was attained from the distal duodenum though a few studies 375 
that sampled from the proximal jejunum were also included. Adult pH is depicted as mean values from 376 
separate investigations, as summarized by Fuchs and Dressman (39).  Studies investigating intestinal pH 377 
in children, especially in the youngest age groups, were not widely published in the literature. In addition, 378 
data obtained from adults encompassed a large degree of variability. Consequently, no distinct 379 
relationship between age and fasted-state intestinal pH was observed. Pediatric media were subsequently 380 
formulated using the same pH as denoted for the adult reference media (i.e. FaSSIF – pH = 6.5)  381 
Fasting bile salt concentrations from the proximal small intestine are depicted as a function of age 382 
in Figure 3b. A large degree of variability was apparent in both children and adults as denoted by the 383 
spread of data. Discernable differences between pediatric age groups (i.e. neonates, infants) and adults 384 
were not visually evident. Furthermore, the linear association between the logarithm of age and bile acid 385 
concentrations was negligible (R2=0.05) among pediatrics. Due the substantial degree of variability 386 
between pediatric studies, P-FaSSIF was developed to assess two potential scenarios. In one media, bile 387 
salt concentrations were formulated to be 150% of adult values. In the second media, concentrations 388 
were formulated to be 50% lower than adults. A pediatric media where bile salt concentrations were 389 
similar to adult values did not necessitate development of a new media as this scenario was already 390 
depicted by the adult reference. Developed media represent hypothetical depictions of bile acid 391 
concentrations within a biologically plausible range. Correspondingly, the magnitude of compound 392 
specific solubility differences denoted in such media provides an indication of whether additional pediatric 393 
investigations are required to define bile acids within the fasted-state intestine. 394 
No pediatric data pertaining to phospholipids (i.e. lecithin), buffering capacity, and osmolality of 395 
intestinal fluids in the fasted-state were ascertained.  Pediatric media were therefore formulated to 396 
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maintain the same [NaTc]/[lecithin] ratio as depicted in the adult reference media (FaSSIF). Buffering 397 
capacity and osmolality were also defined using adult values. Compositions of the proposed P-FaSSIF 398 
media are presented in Table VII. 399 
Pediatric Fed-State Simulated Intestinal Fluid (P-FeSSIF): 400 
Fed-state duodenal pH values from separate pediatric and adult investigations are presented in 401 
Figure 4a.  Of the few studies presented amongst pediatrics, pH values appear to overlap with those 402 
depicted from adults. Owing to the disparate nature of available data, pH differences between each age 403 
group (neonate, infants, and adult) could not be fully elucidated. Pediatric FeSSIF media were therefore 404 
formulated using the same pH as the adult reference (i.e. pH = 5.8). 405 
Assessments of postprandial intestinal osmolality amongst pediatrics were also scarcely published 406 
within the literature. A single study conducted by Billeaud et al. (36), which was also utilized to define 407 
pediatric FeSSGF osmolality, was identified. Duodenal osmolality was assessed in 15 low birth weight 408 
neonates following administration of a variety of feeds, each varying in osmolality. A positive linear 409 
association between feed and duodenal osmolality was found. A regression model was constructed using 410 
a congruent approach as previously discussed for defining FeSSGF osmolality (Figure 4b). Although a 411 
suitable coefficient of determination (R2 = 0.92) between feed osmolality and 60 minute postprandial 412 
duodenal osmolality was attained, a second study from which the model could be evaluated within 413 
pediatrics was unavailable. As an alternative assessment, the model was utilized to estimate to duodenal 414 
osmolality in two adult studies. Mean duodenal osmolality values of approximately 405 and 392 mOsm/kg 415 
were observed 1 hour following administration of liquid meals containing 610 and 670 mOsm/kg in 416 
separate investigations conducted by Kalantzi et al. (33) and Clarysse et al. (40), respectively. The 417 
proposed regression model provided duodenal osmolality estimates of 430 (6% over-prediction) and 454 418 
(16% over-prediction) mOsm/kg for each respective adult investigation. Although derived from a cohort 419 
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of neonatal subjects, the model exhibited an adequate predictive capacity in adults. By extension, its use 420 
for estimating intestinal osmolality amongst pediatrics (neonates and infants) was considered to be 421 
appropriate. The osmolality of neonatal FeSSIF was formulated to reflect two separate feed types, breast 422 
milk, with a reported osmolality of ~300 mOsm/kg (36, 41), and cow’s milk-based formula with a measured 423 
osmolality of 368 mOsm/kg (Cow & Gate First Infant Milk). For FeSSIF reflective of older children (i.e. 424 
infants) where weaning is commonly instituted, only a single feed type was investigated, cow’s milk 425 
formula. Using the aforementioned regression equation, osmolality of the developed pediatric FeSSIF was 426 
defined as 300 and 330 mOsm/kg post-administration of breast milk and cow’s milk-based formula, 427 
respectively. 428 
Fed-state duodenal bile salt concentrations among pediatrics and adults are summarized in Figure 429 
4c. A positive linear association between the logarithm of age and duodenal bile acid concentrations was 430 
denoted among children (R2 = 0.54). Bile acid concentrations among adults displayed variability, but for 431 
the most part studies depicted a mean value of approximately 10 mM, corresponding to the concentration 432 
of the reference adult media (FeSSIF v2). Mean bile acid concentrations among neonates (0-28 days) and 433 
infants (1-12m) were approximately 25% (i.e. 2.5 mM) and 75% (i.e. 7.5 mM) of adult values, respectively. 434 
Pediatric FeSSIF were subsequently formulated using these bile acid concentrations. 435 
Pediatric studies characterizing concentrations of fat digestion products in the intestinal lumen 436 
have not been reported in the literature. However, since the quantity of such products is dependent on 437 
the interrelationship between fat digestion and absorption, an examination of these processes was 438 
instituted in order to derive age-dependent estimates. In newborns, concentrations of pancreatic 439 
colipase-dependent triglyceride lipase, the enzyme primarily responsible for lipid metabolism in adults, is 440 
decreased (42). Despite this, the presence of auxiliary enzymes such as human gastric lipase, pancreatic 441 
lipase-related protein 2 and bile salt-stimulated lipase, are postulated to provide an efficient means of 442 
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lipid digestion for newborns (42).  In terms of absorption, breast-fed neonates exhibit fat absorption 443 
coefficients reminiscent to that of adults despite lower duodenal bile acid concentrations (43). It was 444 
therefore inferred that the developmental capacity of both fat digestion and absorption were comparable 445 
to adults amongst this pediatric cohort. FeSSIF media reflective of breast-fed neonates were 446 
correspondingly formulated using the same concentrations lipid digestion products (glyceryl monooleate 447 
and sodium oleate) as defined for the adult reference media (i.e. FeSSIF). 448 
However, among formula-fed neonates, fat absorption coefficients are notably lower compared 449 
to their breast-fed counterparts as well as adults (43, 44).  Unlike breast-fed neonates, intestinal bile 450 
concentrations in formula-fed neonates were found to exhibit a positive linear correlation with percent 451 
fat absorption (43, 44). To decipher whether a deficiency in lipid absorption or lipid digestion was the 452 
primary factor limiting internalization of fats in formula-fed neonates, pathophysiological information 453 
pertaining to necrotizing entercolitis (NEC) was used. NEC is a debilitating inflammatory GI condition 454 
occurring typically in preterm neonates but also uncommonly in term neonates. In both groups, the 455 
incidence of NEC is substantially higher in formula-fed subjects as compared to those receiving enteral 456 
feeds with breast milk (45, 46). Though the mechanism of pathogenesis of NEC is not completely 457 
understood, one theory as described by the work published by Penn et al. (47) identified the presence of 458 
elevated concentrations of free fatty acid (FFA) as the culpable factor. The study found lipase digestion of 459 
formula, but not human milk, exhibited a cytotoxic effect in three different cell types. Furthermore, 460 
digested formula displayed significantly greater levels of FFA compared to lipase digested human milk. 461 
Based on this finding in conjunction the prevalence of NEC amongst the youngest cohort of neonates, it 462 
was inferred that the process of lipid digestion was not developmentally impaired in formula-fed 463 
neonates. Hence, the decreased capacity for fat internalization was attributed to an inadequate lipid 464 
absorptive capacity in such subjects. Correspondingly, formula-fed neonates would be expected to exhibit 465 
higher luminal concentrations of lipid digestion products. Using 75% as the average coefficient of fat 466 
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absorption in formula-fed neonates (42-44), the concentration of lipid digestion products (glyceryl 467 
monooleate and sodium oleate) was estimated to be 1.33x (i.e. 1/0.75) greater in the intestinal lumen of 468 
neonates that are formula-fed compared those that are breast-milk fed.  P-FeSSIF media pertaining to 469 
formula-fed neonates was developed based on the above assertion. In infants, where luminal bile acid 470 
concentrations are higher, fat absorption is not expected to exhibit developmental impairment. Pediatric 471 
FeSSIF reflective of formula fed infants was therefore formulated using the same concentrations of fat 472 
digestion products as depicted for the adult reference media. 473 
No pediatric studies investigating buffering capacity and concentrations of phospholipids (i.e 474 
lecithin) within the fed-state intestinal lumen were obtained. Buffering capacity of the developed 475 
pediatric media were consequently formulated using a value of 25 mEq/L/ ∆pH, the adult reference value.  476 
Using a similar approach as employed for P-FaSSGF and P-FaSSIF, lecithin concentrations were fixed to 477 
provide the same ratio of [NaTc]/[lecithin] as expressed by the reference adult media (i.e. FeSSIF.v2). The 478 
compositional details of developed P-FeSSIF media are depicted in Table VIII. 479 
 480 
Solubility Assessments: 481 
Solubility determinations for six of the seven compounds (carbamazepine, dapsone, griseofulvin, 482 
indomethacin, phenytoin and spironolactione) were conducted in age-specific media representative of all 483 
four gastrointestinal states: FaSSGF, FeSSGF, FaSSIF and FeSSIF (Figure 5). For fenofibrate, use of the 484 
predefined equilibrium dialysis method did not serve as a suitable technique for solubility determinations 485 
in fed-state gastric media. Penetration of fenofibrate through the dialysis membrane was inefficient 486 
during the selected study interval (96 hours) and, as a result, solubility could not quantified. Figure 6 487 
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depicts solubility determinations of fenofibrate in age-specific media reflective of the remaining three 488 
gastrointestinal states: FaSSGF, FaSSIF and FeSSIF.  489 
For pediatric media representative of the fasted gastric state (i.e. P-FaSSGF), three compounds 490 
(carbamazepine, indomethacin and fenofibrate) exhibited mean solubility values below the 80 to 125% 491 
reference range, relative to adults. Though for indomethacin, this difference was not statistically 492 
significant. Relative solubility changes depicted between neonatal and infant FaSSGF were consistent in 493 
terms of direction and magnitude for six of seven compounds. Only one compound, carbamazepine, 494 
displayed a statistically significant difference in solubility between neonatal and infant FaSSGF.  495 
Solubility assessments in neonatal fed-state gastric media (i.e. P-FeSSGF), developed using cow’s 496 
milk-based or soy-based formula, were compared to solubilities attained in adult FeSSGF formulated with 497 
cow’s milk. Five compounds (carbamazepine, dapsone, griseofulvin, phenytoin and indomethacin) 498 
exhibited changes in solubility that fell outside the aforementioned reference range in at least one of the 499 
developed neonatal media.  A trend towards lower solubility values in neonatal media was found for four 500 
of the compounds (carbamazepine, dapsone, griseofulvin and phenytoin). For indomethacin, a weak acid 501 
(pKa = 4.5), an increase in solubility compared to adult media was observed that was attributed, in part, 502 
to the higher pH of neonatal FeSSGF. Statistically significant differences in solubility between neonatal 503 
media formulated using either cow’s milk-based or soy-based formula was observed in 4/6 compounds. 504 
For carbamazepine, solubility values in media comprised with cow’s milk formula was greater than that 505 
of media comprised with soy formula. For dapsone, phenytoin and indomethacin the opposite was 506 
observed. In contrast, for spironolactone and griseofulvin, no statistically significant difference in 507 
compound solubility was noted between the respective neonatal media. 508 
Since a consensus regarding differences in bile salt concentrations between children and adults 509 
within the fasted-state intestine was not achieved, compound solubility was investigated based on two 510 
24 
 
theoretical media that incorporated bile salt concentrations of 150% (4.5 mM) and 50% (1.5 mM) of those 511 
in adults. For the majority of compounds (6/7), solubility determinations in both media fell within an 80% 512 
to 125% range when compared to adult values. However, for fenofibrate (logP = 5.3), solubility in P-FaSSIF-513 
50% media was 56% of the value observed in the adult reference. 514 
Solubility determinations conducted in pediatric media reflective of the fed-state intestine (i.e. P-515 
FeSSIF) were compared to values attained in adult FeSSIF. For three of seven compounds (fenofibrate, 516 
griseofulvin and phenytoin), mean solubilities of less than 80% of adult values were observed in at least 517 
one of the formulated P-FeSSIF.  These relevant solubility alterations were exclusively found in neonatal 518 
media. In comparison, mean solubility values in infant FeSSIF fell within 80-125% of adult values for all 519 
compounds investigated. A general trend towards statistically significant lower solubilities in neonatal 520 
media compared to infant FeSSIF was observed in five of seven compounds. Statistically significant 521 
solubility differences between neonatal media formulated to depict intestinal fluids following 522 
administration of cow’s milk-based formula (Pnc-FeSSIF) or breast milk (Pnb-FeSSSIF) were denoted for 523 
three compounds (griseofulvin, spironolactone, and phenytoin). A higher solubility was observed for 524 
griseofulvin in Pnc-FeSSIF though in both neonatal media, values were below the 80-125% reference 525 
range. Solubility was also greater in Pnc-FeSSIF for spironolactone but, in this case, solubility values in 526 
both media fell within the 80-125% reference range. In contrast, for phenytoin, a higher solubility was 527 
observed in Pnb-FeSSIF. Solubility in Pnb-FeSSIF fell within 80-125% of adult values, but for media 528 
depicting formula-fed neonates (Pnc-FeSSIF), the mean solubility was well below the 80% reference point. 529 
  Changes in compound solubility between pediatric and adult media induced by alterations in bile 530 
salt concentrations were estimated according to the equations proposed by Mithani et al (17). These 531 
values are displayed in Figures 5 and 6 (red dots) for media formulated with NaTc (i.e. FaSSGF, FaSSIF, and 532 
FeSSIF). Table IX displays RMSE values between predicted and measured solubility ratios for the 533 
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developed pediatric media in order of increasing compound lipophilicity. For the two least lipophilic 534 
compounds investigated (dapsone and griseofulvin), predictions made using Mithani el al.’s equations 535 
were within a RMSE of 10%. In these cases, the equations provide an acceptable approximation of the 536 
direction and magnitude of solubility changes observed in pediatric media. As compound lipophilicity 537 
increased, a departure between predicted and measured solubility ratios was observed as indicated by 538 
larger RMSE values. For such compounds, the predicted magnitude of solubility changes due to alterations 539 
in media NaTc content were typically overstated when compared to measured values. 540 
Discussion: 541 
Based on an assessment of the current literature, biorelevant media simulating the unique 542 
intricacies of the upper gastrointestinal tract (stomach and proximal small intestine) in pediatrics were 543 
developed and utilized to estimate compound specific solubility. Preferably, solubility comparisons 544 
between pediatrics and adults should be conducted using ex-vivo luminal fluid samples, but due to the 545 
numerous logistical and ethical constraints associated with obtaining of such samples in pediatrics, the 546 
use of biorelevant media was deemed as a suitable approach. In adults the appropriateness of biorelevant 547 
media has been established by investigations depicting strong positive correlations in compound solubility 548 
between simulated and human intestinal fluids (48, 49).  549 
Pediatric fed-state gastric media (P-FeSSGF) was formulated using either cow’s milk-based or soy-550 
based formula to assess the impact of feed type on compound solubility. The use of human breast milk 551 
within the investigation was precluded due to logistic issues associated sample obtainment and 552 
uniformity. In terms of uniformity, the composition human breast milk is well known to exhibit both intra- 553 
and inter-subject variability in composition (50). Infant formulas, however, are subject to quality control 554 
inspections to ensure batch-to-batch uniformity, ensuring biorelevant media are prepared in a 555 
reproducible fashion. Marketed infant formulas are designed to mimic the composition of human breast 556 
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milk with regards to the proportions of energy provided from protein, fats, and carbohydrates (51).  In 557 
human breast milk, proteins are predominantly comprised of two forms, whey and casein, in a ratio of 558 
60:40, respectively. In contrast, the whey-to-casein ratio of cow’s milk is 18:82 (51). To address this 559 
discrepancy, many formulas, including Cow & Gate First Infant Milk (cow’s milk based), have introduced 560 
additional amounts of whey protein in order to mimic ratios observed in human milk (51). The influence 561 
of casein on compound solubility has previously been depicted for the anticoagulant dicumarol, where 562 
increases in casein concentration corresponded to higher dicumarol solubility values (52). Despite 563 
supplementation with vitamins and minerals, infant formula cannot fully reproduce the biological 564 
complexity of human breast milk which contains antibodies, enzymes, and growth factors (51). However, 565 
cow’s milk formula does provide a suitable approximation in terms of macronutrient composition and 566 
protein type that is free from the inherent variability associated with breast milk. As such, solubility studies 567 
conducted in neonatal FeSSGF comprised with cow’s milk formula may encompass applicability towards 568 
breast fed neonates. 569 
 Concentrations of media components were formulated to represent the average tendency over a 570 
specific age range. To summarize age-specific data from the literature, the investigation utilized non-571 
weighted arithmetic means. Though simplistic in nature, use of the arithmetic mean was preferred over 572 
other more robust computational or statistical analyses based on several considerations. First, there is 573 
the relative disparity of literature investigations devoted to defining the composition of luminal fluids in 574 
pediatrics compared to adults. For many media components only a handful of studies were available to 575 
quantify differences between subsequent age groups. Of studies obtained, high degrees of variability 576 
were typically noted. This is likely attributed to the dynamic nature of the developmental process, where 577 
the composition of luminal fluids continually change as children mature. Due to this disparity of available 578 
data and its inherent variability, employment of statistical tests to identify significant differences in 579 
component concentrations between adjacent age groups were not applicable. Similarly, the use of 580 
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regression analyses were typically unable to establish meaningful correlations between parameter values 581 
and age. A second consideration for the preferential use of non-weighted arithmetic means was due to 582 
the precarious nature of qualifying investigations. A large majority of pediatric studies were completed 583 
over three decades ago, where differences in reporting standards and quantitative techniques were wide-584 
ranging. Employment of a non-weighted approach was instituted to simplify the analysis though, 585 
understandably, the method lacks the informative capacity of approaches that consider study quality, as 586 
frequently adopted by systematic reviews (53). Finally, studies varied in terms of data presentation, 587 
making implementation of weighted averages difficult. Reporting of variability associated with luminal 588 
fluids components was inconsistent between investigations. For example, separate studies utilized a 589 
variety of measures including standard deviation, range, or interquartile range. Additionally, the number 590 
of subjects allocated to specific age ranges were not identified by some investigators (21). Due to this lack 591 
of consistency between studies, employment of a weighted mean was precluded in favor of a non-592 
weighted approach. As the arithmetic mean does not provide an indication of parameter variability, the 593 
analysis is unable to depict expected variations within the population. However, as biorelevant media is 594 
developed to represent luminal fluids in an average individual, descriptions of parameter variability were 595 
unnecessary. 596 
 Due to the disparate nature of available pediatric data, the quantitative value of many media 597 
components were based on biological inferences or adoption of adult values. For example pediatric 598 
investigations pertaining to luminal concentrations of pepsin, phospholipids, fat digestion products, and 599 
osmolality were either scarcely reported or lacking within the literature. The proposed age-specific media 600 
attempted to approximate the in vivo composition of pediatric luminal fluids based on a current state of 601 
knowledge. As future investigations are obtained, such formulations should undoubtedly be modified to 602 
provide greater degrees of biological relevance. 603 
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 In addition to its primary goal of facilitating suitable IVIVC, biorelevant media should demonstrate 604 
a practical degree of stability.  Apart from noticeable changes in visual appearance, media stability can be 605 
formally evaluated by assessing for alterations in physicochemical parameters under ambient and test 606 
conditions. In Jantratid et al.’s original publication (2), which described the reference adult media utilized 607 
by this investigation, stability was evaluated through measurements of media pH, buffering capacity and 608 
osmolality. For adult FeSSGF and FeSSIF-v2, consistency in physicochemical parameters were observed 609 
under ambient conditions over a 72 hour study period. In addition, with the exception of minor changes 610 
in osmolality, the abovementioned media demonstrated stability under test conditions of 37OC over the 611 
same time period. Changes in media physicochemical properties (i.e. poor stability) during solubility 612 
assessments may lead to corresponding changes in compound specific saturation solubility. In the current 613 
investigation, solubility assessments in fed-state simulated gastric media comprised of cow’s milk 614 
(FeSSGF) and infant formula (neonatal FeSSGF) were conducted at 37oC after 48 hours for most 615 
compounds. Though stability studies were not conducted within the developed pediatric FeSSGF, it was 616 
inferred that stability would be similar to that of adult FeSSGF. However, if large scale implementation of 617 
the depicted pediatric media is desired, future research evaluating media stability will certainly be 618 
required.   619 
For the majority of study compounds, solubility assessments proceeded without issue. Though for 620 
fenofibrate, the most lipophilic compound evaluated (logP = 5.3), logistic issues materialized with 621 
solubility determinations in biorelevant media reflective of the fed gastric state. For FeSSGF media, the 622 
study employed equilibrium dialysis to assess compound solubility. Though this technique proved 623 
effective for most compounds, it was unsuitable for fenofibrate.  Following a 96 hour dwell period, 624 
fenofibrate concentrations within the membrane were below the limit of quantification. This result may 625 
indicate inadequate permeation of the dialysis membrane by fenofibrate in milk or formula-based 626 
samples. A congruent example is demonstrated by the in vivo pharmacokinetics of fenofibrate. In humans, 627 
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fenofibrate exhibits extensive protein binding (~99%) and, as such, filtration by hemodialysis is not 628 
considered effective (54, 55). Based on this assessment, use of equilibrium dialysis was not considered 629 
feasible for determination of fenofibrate solubility in fed state gastric media. These values were 630 
correspondingly excluded from the analysis. 631 
Solubility assessments were confined to BCS Class II compounds, where limitations in absorption 632 
are primarily attributed to inadequate drug solubility. For such compounds, differences in luminal 633 
solubility may signify alterations in oral drug performance (56). To maintain a degree of biological 634 
relevance, the analysis was further limited to compounds where documented or investigational uses in 635 
both children and adults have been depicted. To identify relevant changes in the age-specific solubility, 636 
the study utilized the same threshold as depicted by the US-FDA for attainment of in vivo bioequivalence 637 
(i.e. 80-125%) (16).  It should be noted, however, that solubility in only one parameter which can exert an 638 
effect on oral compound absorption. Other parameters including gastric emptying time, small intestinal 639 
transit time, intestinal permeability, gut metabolism, luminal degradation and presence of intestinal 640 
transporters may also impart an influence in vivo. In order to fully elucidate the impacts of growth and 641 
development on oral compound absorption, a more comprehensive analyses such as physiologically-642 
based pharmacokinetic (PBPK) modeling would be required to integrate age-dependencies in all the 643 
aforementioned parameters. The presented analysis which focusses on biorelevant solubility as a 644 
surrogate for oral compound performance was therefore an overt simplification. However, this approach 645 
was justified based on the cohort of compounds assessed, which was confined to solubility-limited (BCS 646 
Class II) drugs.  647 
Compared to adult media, solubility in pediatric fasted-state gastric media (i.e. P-FaSSGF) was 648 
both statistical different (p≤0.05) and outside the purported bioequivalence criterion for two compounds, 649 
fenofibrate and carbamazepine. For fenofibrate, mean solubility values in adult FaSSGF and pure water 650 
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were comparable at 0.281 and 0.206 mcg/mL, respectively. In contrast, solubility within adult fasted-state 651 
intestinal media (i.e. FaSSIF) was considerably greater (2.42 mcg/mL). The discrepancy in solubility values 652 
between FaSSGF and FaSSIF provides an indication of the relative influence of each state on modulating 653 
oral absorption. In this case, due to its poor solubility in comparison to intestinal fluids, fasted state gastric 654 
fluids are unlikely to play an influential role on modulating the extent of fenofibrate absorption. Solubility 655 
alterations observed in P-FaSSGF were therefore not postulated to impact the oral performance of 656 
fenofibrate in children.  Differences in solubility between neonatal and infant FaSSGF reached a 657 
statistically significant threshold for only one compound, carbamazepine. Though for both media, the 658 
mean solubility fell outside the bioequivalence threshold when compared to adult values. Based on this 659 
analysis, an argument may be formed as to the need for separate pediatric media since solubilities in 660 
neonate and infant FaSSGF appear to be similar in most cases. The current investigation focused on 661 
solubility, a compound specific property. However, in terms of establishing IVIVC for solid dosage forms, 662 
biorelevant media is typically employed within dissolution tests to assess formulation properties (57). In 663 
addition to modulating solubility, media components that are age-specific may also exert an influence on 664 
the rate of compound release and subsequent dissolution from a formulation. For example, the addition 665 
of pepsin into biorelevant media has been demonstrated to decrease surface tension (3). For specific 666 
formulations, such changes can exert of an effect on the rate of compound dissolution (58). Also, the 667 
presence of pepsin within dissolution media can facilitate effective compound release from cross-linked 668 
gelatin capsules (59). Therefore, although comparable solubilities were observed for neonatal and infant 669 
FaSSGF media, use of separate age-specific media may be justified for use in dissolution testing. 670 
Solubility assessments in age-specific FeSSGF media were conducted for six compounds.  For the 671 
majority of compounds (5/6), the mean solubility in neonatal media, comprised of either cow’s milk-based 672 
or soy-based formula, fell outside the 80-125% bioequivalence criterion in relation to adult media 673 
comprised of milk. In addition, statistically significant differences in compound solubility between 674 
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pediatric media comprised with cow’s milk-based and soy-based formula were observed in four 675 
compounds. These results infer that differences in feed composition between children as well as between 676 
children and adults can impart relevant changes in gastric solubility and, potentially, affect oral compound 677 
performance. 678 
Of the limited pediatric investigations examining luminal fluids within the fasted-state proximal 679 
intestine, bile salt concentrations were found to exhibit a high degree of variability without any apparent 680 
age dependency. To explore the impact of such variations, two FaSSIF media were developed with bile 681 
salt concentrations of 50% (1.5 mM) and 150% (4.5 mM) of adult values. For the majority of compounds 682 
(6/7), mean solubility values within the two proposed P-FaSSIF media fell within an 80-125% range from 683 
adult values. However for the most lipophilic compound, fenofibrate (logP = 5.3), solubility in P-FaSSIF 684 
media containing 1.5 mM NaTc was 56% of adult values. If such a media is reflective of in vivo luminal 685 
fluids in children, the observed change in solubility may signify an alteration in fenofibrate oral 686 
performance compared to adults. Prospectively, hydrophobic compounds are expected to play an 687 
increasingly important role in therapeutics as use of drug discovery techniques such a high-throughput 688 
screening typically produces candidate compounds of higher lipophilicity (60). To provide an accurate 689 
depiction of luminal solubility for such compounds, a consensus regarding intestinal bile salt 690 
concentrations in pediatrics is needed. This demonstrates a need for more high quality studies 691 
characterizing gastrointestinal physiology in pediatrics. 692 
Solubility assessments conducted in fed-state intestinal media representative of infants were 693 
within 80-125% of adult values for all 7 compounds tested. Such a result was unsurprising as infant and 694 
adult media were compositionally similar, aside from small deviations in bile salt content, lecithin, and 695 
osmolality. Two neonatal media were formulated to reflect differences in intestinal fluid composition 696 
following administration of breast milk or cow’s milk-based formula. Mean compound solubility values in 697 
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neonatal media fell outside the 80-125% criterion from adult values for 3 of the 7 compounds examined. 698 
Statistically significant differences in solubility between media reflective of breast-fed and formula-fed 699 
neonates was observed for 3 compounds. The relative magnitude of these differences appeared to be 700 
compound specific. For example, spironolactone solubility in intestinal media reflective of breast and 701 
formula fed neonates were 83% vs. 91% of adult values, respectively. In contrast, for phenytoin a larger 702 
discrepancy between solubility ratios was observed (92% vs. 61% of adult values, respectively). These 703 
findings demonstrate the potential impact of different feed types on intestinal compound solubility.  704 
The study also included an evaluation the relative importance of bile salts in modulating 705 
compound solubility within the developed pediatric media. Predictive equations presented by Mithani et 706 
al. (17) were used to estimate the impact of alterations in bile salt content on compound solubility. 707 
Measured solubility values, which are influenced by all media components, were compared to estimated 708 
values, which only account for differences in media bile salts, using RMSE. The analysis demonstrated a 709 
decreased predictive capacity of the aforementioned equations (ie. larger RMSE values) as compound 710 
lipophilicity (logP) increased. This indicates that as compound lipophilicity increases, other media 711 
components, aside from bile salts, exert a more pronounced role in modulating compound solubility. For 712 
example, the capacity of media components such as buffer (sodium phosphate), fat digestion products 713 
(sodium oleate) and salt (sodium chloride) to modify compound solubility has previously been 714 
demonstrated within the literature (10).  715 
Conclusion: 716 
The current investigation strove to appropriately depict the in vivo composition pediatric luminal 717 
fluids based on the current literature and represents an initial foray into the development of pediatric 718 
biorelevant media.  To increase the biological applicability of future iterations of such media, it is clear 719 
prospective studies focused on defining the composition of the pediatric lumen under varying conditions 720 
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is required. For 6 of the 7 BCS Class II compounds investigated, solubility fell outside an 80-125% range 721 
from adult values in at least one of the developed pediatric media. This result demonstrates the impact 722 
of age-related alterations in GI fluid composition on compound solubility. Solubility represents an integral 723 
component of the BCS, a framework which is extensively utilized by both industry and regulatory bodies 724 
to guide drug development in adults. The utility of a similar classification system in pediatrics is in part 725 
contingent on our understanding of how developmental differences between children and adults 726 
translates to alterations definable properties such compound solubility. The investigation sought to 727 
address this concern and, in turn, provides a dialogue surrounding the future development of a pediatric-728 
focused BCS.   729 
Acknowledgements: 730 
This work was funded by the Natural Sciences and Engineering Research Council of Canada 731 
(NSERC). The authors would also like to express their gratitude to Sarah Cordery for her guidance within 732 
the laboratory and Fotios Baxevanis for his assistance with the analysis. 733 
 734 
 735 
 736 
 737 
 738 
 739 
 740 
34 
 
1. Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB. Evaluation of various 741 
dissolution media for predicting in vivo performance of class I and II drugs. Pharmaceutical research. 1998 742 
May;15(5):698-705. 743 
2. Jantratid E, Janssen N, Reppas C, Dressman JB. Dissolution media simulating conditions in the 744 
proximal human gastrointestinal tract: an update. Pharmaceutical research. 2008 Jul;25(7):1663-76. 745 
3. Vertzoni M, Dressman J, Butler J, Hempenstall J, Reppas C. Simulation of fasting gastric conditions 746 
and its importance for the in vivo dissolution of lipophilic compounds. European journal of pharmaceutics 747 
and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik eV. 748 
2005 Aug;60(3):413-7. 749 
4. Shono Y, Jantratid E, Janssen N, Kesisoglou F, Mao Y, Vertzoni M, et al. Prediction of food effects 750 
on the absorption of celecoxib based on biorelevant dissolution testing coupled with physiologically based 751 
pharmacokinetic modeling. EurJPharmBiopharm. 2009 9/2009;73(1):107-14. 752 
5. Dressman JB, Reppas C. In vitro-in vivo correlations for lipophilic, poorly water-soluble drugs. 753 
European journal of pharmaceutical sciences : official journal of the European Federation for 754 
Pharmaceutical Sciences. 2000 Oct;11 Suppl 2:S73-80. 755 
6. Kaye JL. Review of paediatric gastrointestinal physiology data relevant to oral drug delivery. 756 
International journal of clinical pharmacy. 2011 Feb;33(1):20-4. 757 
7. Mooij MG, de Koning BA, Huijsman ML, de Wildt SN. Ontogeny of oral drug absorption processes 758 
in children. Expert opinion on drug metabolism & toxicology. 2012 Oct;8(10):1293-303. 759 
8. Abdel-Rahman SM, Amidon GL, Kaul A, Lukacova V, Vinks AA, Knipp GT. Summary of the National 760 
Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric 761 
Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group. 762 
ClinTher. 2012 11/2012;34(11):S11-S24. 763 
9. Amidon GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutic drug 764 
classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. PharmRes. 765 
1995 3/1995;12(3):413-20. 766 
10. Khadra I, Zhou Z, Dunn C, Wilson CG, Halbert G. Statistical investigation of simulated intestinal 767 
fluid composition on the equilibrium solubility of biopharmaceutics classification system class II drugs. 768 
European journal of pharmaceutical sciences : official journal of the European Federation for 769 
Pharmaceutical Sciences. 2015 Jan 25;67:65-75. 770 
11. Hentges DJ, Marsh WW, Petschow BW, Thai WR, Carter MK. Influence of Infant Diets on the 771 
Ecology of the Intestinal Tract of Human Flora-Associated Mice. Journal of Pediatric Gastroenterology and 772 
Nutrition. 1992;14(2):146-52. 773 
12. Van Slyke DD. On the measurement of buffer values on the relationship of buffer values to the 774 
dissociation constant of the buffer and the concentration and reaction of the buffer solution. J Biol Chem. 775 
1922;52:525-70. 776 
13. Granero GE, Ramachandran C, Amidon GL. Dissolution and solubility behavior of fenofibrate in 777 
sodium lauryl sulfate solutions. Drug development and industrial pharmacy. 2005 Oct;31(9):917-22. 778 
14. Vogt M, Kunath K, Dressman JB. Dissolution enhancement of fenofibrate by micronization, 779 
cogrinding and spray-drying: comparison with commercial preparations. European journal of 780 
pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische 781 
Verfahrenstechnik eV. 2008 Feb;68(2):283-8. 782 
15. Juenemann D, Bohets H, Ozdemir M, de Maesschalck R, Vanhoutte K, Peeters K, et al. Online 783 
monitoring of dissolution tests using dedicated potentiometric sensors in biorelevant media. European 784 
journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur 785 
Pharmazeutische Verfahrenstechnik eV. 2011 May;78(1):158-65. 786 
35 
 
16. Guidance for industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug 787 
Products — General Considerations. U.S. Department of Health and Human Services. Food and Drug 788 
Administration. Center for Drug Evaluation and Research.; 2003. 789 
17. Mithani SD, Bakatselou V, TenHoor CN, Dressman JB. Estimation of the increase in solubility of 790 
drugs as a function of bile salt concentration. Pharmaceutical research. 1996 Jan;13(1):163-7. 791 
18. James LP, Marotti T, Stowe CD, Farrar HC, Taylor BJ, Kearns GL. Pharmacokinetics and 792 
pharmacodynamics of famotidine in infants. Journal of clinical pharmacology. 1998 Dec;38(12):1089-95. 793 
19. James LP, Marshall JD, Heulitt MJ, Wells TG, Letzig L, Kearns GL. Pharmacokinetics and 794 
pharmacodynamics of famotidine in children. Journal of clinical pharmacology. 1996 Jan;36(1):48-54. 795 
20. Krafte-Jacobs B, Persinger M, Carver J, Moore L, Brilli R. Rapid placement of transpyloric feeding 796 
tubes: a comparison of pH-assisted and standard insertion techniques in children. Pediatrics. 1996 797 
Aug;98(2 Pt 1):242-8. 798 
21. Gharpure V, Meert KL, Sarnaik AP, Metheny NA. Indicators of postpyloric feeding tube placement 799 
in children. Crit Care Med. 2000 8/2000;28(8):2962-6. 800 
22. Westhus N. Methods to test feeding tube placement in children. MCN The American journal of 801 
maternal child nursing. 2004 Sep-Oct;29(5):282-7; quiz 90-1. 802 
23. Metheny NA, Stewart BJ, Smith L, Yan H, Diebold M, Clouse RE. pH and concentrations of pepsin 803 
and trypsin in feeding tube aspirates as predictors of tube placement. JPEN Journal of parenteral and 804 
enteral nutrition. 1997 Sep-Oct;21(5):279-85. 805 
24. Arvedson JC. Swallowing and feeding in infants and young children.  Goyal and Shaker's GI motility 806 
online. New York Nature Publishing Group; 2006. 807 
25. Agunod M, Yamaguchi N, Lopez R, Luhby AL, Glass GB. Correlative study of hydrochloric acid, 808 
pepsin, and intrinsic factor secretion in newborns and infants. The American journal of digestive diseases. 809 
1969 Jun;14(6):400-14. 810 
26. Di Maio S, Carrier RL. Gastrointestinal contents in fasted state and post-lipid ingestion: in vivo 811 
measurements and in vitro models for studying oral drug delivery. J Control Release. 2011 Apr 812 
30;151(2):110-22. 813 
27. Wakayama Y, Wilkins S, Kimura K. Is 5% dextrose in water a proper choice for initial postoperative 814 
feeding in infants? Journal of pediatric surgery. 1988 Jul;23(7):644-6. 815 
28. Muller-Lissner SA, Fimmel CJ, Sonnenberg A, Will N, Muller-Duysing W, Heinzel F, et al. Novel 816 
approach to quantify duodenogastric reflux in healthy volunteers and in patients with type I gastric ulcer. 817 
Gut. 1983 Jun;24(6):510-8. 818 
29. Rees WD, Go VL, Malagelada JR. Simultaneous measurement of antroduodenal motility, gastric 819 
emptying, and duodenogastric reflux in man. Gut. 1979 Nov;20(11):963-70. 820 
30. Klein S. The use of biorelevant dissolution media to forecast the in vivo performance of a drug. 821 
The AAPS journal. 2010 Sep;12(3):397-406. 822 
31. Klein S, Butler J, Hempenstall JM, Reppas C, Dressman JB. Media to simulate the postprandial 823 
stomach I. Matching the physicochemical characteristics of standard breakfasts. The Journal of pharmacy 824 
and pharmacology. 2004 May;56(5):605-10. 825 
32. Dressman JB, Amidon GL, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug 826 
absorption: immediate release dosage forms. PharmRes. 1998 1/1998;15(1):11-22. 827 
33. Kalantzi L, Goumas K, Kalioras V, Abrahamsson B, Dressman JB, Reppas C. Characterization of the 828 
human upper gastrointestinal contents under conditions simulating bioavailability/bioequivalence 829 
studies. Pharmaceutical research. 2006 Jan;23(1):165-76. 830 
34. Dressman JB, Berardi RR, Dermentzoglou LC, Russell TL, Schmaltz SP, Barnett JL, et al. Upper 831 
gastrointestinal (GI) pH in young, healthy men and women. PharmRes. 1990 7/1990;7(7):756-61. 832 
36 
 
35. Sondheimer JM, Clark DA, Gervaise EP. Continuous Gastric pH Measurement in Young and Older 833 
Healthy Preterm Infants Receiving Formula and Clear Liquid Feedings. Journal of Pediatric 834 
Gastroenterology and Nutrition. 1985;4(3):352-5. 835 
36. Billeaud C, Senterre J, Rigo J. Osmolality of the gastric and duodenal contents in low birth weight 836 
infants fed human milk or various formulae. Acta paediatrica Scandinavica. 1982 Sep;71(5):799-803. 837 
37. Thatrimontrichai A, Janjindamai W. Postprandial osmolality of gastric contents in very low-birth-838 
weight infants fed expressed breast milk with additives. The Southeast Asian journal of tropical medicine 839 
and public health. 2009 Sep;40(5):1080-6. 840 
38. Miller BR, Tharp JA, Issacs WB. Gastric residual volume in infants and children following a 3-hour 841 
fast. Journal of clinical anesthesia. 1990 Sep-Oct;2(5):301-5. 842 
39. Fuchs A, Dressman JB. Composition and physicochemical properties of fasted-state human 843 
duodenal and jejunal fluid: a critical evaluation of the available data. Journal of pharmaceutical sciences. 844 
2014 Nov;103(11):3398-411. 845 
40. Clarysse S, Tack J, Lammert F, Duchateau G, Reppas C, Augustijns P. Postprandial evolution in 846 
composition and characteristics of human duodenal fluids in different nutritional states. Journal of 847 
pharmaceutical sciences. 2009 Mar;98(3):1177-92. 848 
41. Srinivasan L, Bokiniec R, King C, Weaver G, Edwards AD. Increased osmolality of breast milk with 849 
therapeutic additives. Archives of disease in childhood Fetal and neonatal edition. 2004 Nov;89(6):F514-850 
7. 851 
42. Lindquist S, Hernell O. Lipid digestion and absorption in early life: an update. Current opinion in 852 
clinical nutrition and metabolic care. 2010 May;13(3):314-20. 853 
43. Jarvenpaa AL. Feeding the low-birth-weight infant. IV. Fat absorption as a function of diet and 854 
duodenal bile acids. Pediatrics. 1983 Nov;72(5):684-9. 855 
44. Signer E, Murphy GM, Edkins S, Anderson CM. Role of bile salts in fat malabsorption of premature 856 
infants. Archives of disease in childhood. 1974 Mar;49(3):174-80. 857 
45. Lambert DK, Christensen RD, Henry E, Besner GE, Baer VL, Wiedmeier SE, et al. Necrotizing 858 
enterocolitis in term neonates: data from a multihospital health-care system. Journal of perinatology : 859 
official journal of the California Perinatal Association. 2007 Jul;27(7):437-43. 860 
46. Lucas A, Cole TJ. Breast milk and neonatal necrotising enterocolitis. Lancet. 1990 Dec 22-861 
29;336(8730):1519-23. 862 
47. Penn AH, Altshuler AE, Small JW, Taylor SF, Dobkins KR, Schmid-Schonbein GW. Digested formula 863 
but not digested fresh human milk causes death of intestinal cells in vitro: implications for necrotizing 864 
enterocolitis. Pediatric research. 2012 Dec;72(6):560-7. 865 
48. Clarysse S, Brouwers J, Tack J, Annaert P, Augustijns P. Intestinal drug solubility estimation based 866 
on simulated intestinal fluids: comparison with solubility in human intestinal fluids. European journal of 867 
pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences. 2011 868 
Jul 17;43(4):260-9. 869 
49. Augustijns P, Wuyts B, Hens B, Annaert P, Butler J, Brouwers J. A review of drug solubility in human 870 
intestinal fluids: implications for the prediction of oral absorption. European journal of pharmaceutical 871 
sciences : official journal of the European Federation for Pharmaceutical Sciences. 2014 Jun 16;57:322-32. 872 
50. Hibberd CM, Brooke OG, Carter ND, Haug M, Harzer G. Variation in the composition of breast milk 873 
during the first 5 weeks of lactation: implications for the feeding of preterm infants. Archives of disease 874 
in childhood. 1982 Sep;57(9):658-62. 875 
51. Smith JD, Clinard V, Barnes CL. Pharmacists' guide to infant formulas for term infants. Journal of 876 
the American Pharmacists Association : JAPhA. 2011 May-Jun;51(3):e28-35; quiz e6-7. 877 
52. Macheras PE, Reppas CI. Studies on drug-milk freeze-dried formulations. I: Bioavailability of 878 
sulfamethizole and dicumarol formulations. Journal of pharmaceutical sciences. 1986 Jul;75(7):692-6. 879 
37 
 
53. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled 880 
clinical trials. Bmj. 2001 Jul 7;323(7303):42-6. 881 
54. Chapman MJ. Pharmacology of fenofibrate. The American journal of medicine. 1987 Nov 882 
27;83(5B):21-5. 883 
55. Desager JP, Costermans J, Verberckmoes R, Harvengt C. Effect of hemodialysis on plasma kinetics 884 
of fenofibrate in chronic renal failure. Nephron. 1982;31(1):51-4. 885 
56. Kesisoglou F, Wu Y. Understanding the effect of API properties on bioavailability through 886 
absorption modeling. The AAPS journal. 2008 Dec;10(4):516-25. 887 
57. Fotaki NV, M.;. Biorelevant Dissolution Methods and Their Applications in In Vitro- In Vivo 888 
Correlations for Oral Formulations. The Open Drug Delivery Journal. 2010;4:2-13. 889 
58. Horter D, Dressman JB. Influence of physicochemical properties on dissolution of drugs in the 890 
gastrointestinal tract. Advanced drug delivery reviews. 2001 Mar 1;46(1-3):75-87. 891 
59. Marques MR. Enzymes in the dissolution testing of gelatin capsules. AAPS PharmSciTech. 2014 892 
Dec;15(6):1410-6. 893 
60. Lipinski CA. Drug-like properties and the causes of poor solubility and poor permeability. Journal 894 
of pharmacological and toxicological methods. 2000 Jul-Aug;44(1):235-49. 895 
61. Law V, Knox C, Djoumbou Y, Jewison T, Guo AC, Liu Y, et al. DrugBank 4.0: shedding new light on 896 
drug metabolism. Nucleic Acids Res. 2014 Jan;42(Database issue):D1091-7. 897 
62. Vertzoni MV, Reppas C, Archontaki HA. Sensitive and simple liquid chromatographic method with 898 
ultraviolet detection for the determination of nifedipine in canine plasma. Analytica chimica acta. 2006 899 
Jul 28;573-574:298-304. 900 
63. Parkin JE, Boddy MR. Development of a Chromatographic Method of Analysis for Glucosyl-Amines 901 
Formed from Dapsone. Journal of Liquid Chromatography & Related Technologies. 1998 902 
1998/08/01;21(14):2131-42. 903 
64. Jain N, Raghuwanshi R, Jain D. Development and Validation of RP-HPLC Method for Simultaneous 904 
Estimation of Atorvastatin Calcium and Fenofibrate in Tablet Dosage Forms. Indian journal of 905 
pharmaceutical sciences. 2008 Mar-Apr;70(2):263-5. 906 
65. Trotta M, Gallarate M, Carlotti ME, Morel S. Preparation of griseofulvin nanoparticles from water-907 
dilutable microemulsions. International journal of pharmaceutics. 2003 Mar 26;254(2):235-42. 908 
66. Al Za'abi MA, Dehghanzadeh GH, Norris RL, Charles BG. A rapid and sensitive microscale HPLC 909 
method for the determination of indomethacin in plasma of premature neonates with patent ductus 910 
arteriousus. Journal of chromatography B, Analytical technologies in the biomedical and life sciences. 911 
2006 Jan 18;830(2):364-7. 912 
67. Sanches C, Lopez KV, Omosako CE, Bertoline MA, Pereira MD, Santos S. Micromethod for 913 
Quantification of Carbamazepine, Phenobartital and Phenytoin in Human Plasma by HPLC-UV Detection 914 
for Therapeutic Drug Monitoring Application. Lat Am J Pharm. 2008;27(4):485-91. 915 
68. Jain D, Laxman R, Acharya A, Jain V, Bhardwaj S. Development and validation of RP-HPLC and 916 
ultraviolet spectrophotometric methods for simultaneous determination of sprinolactone and torsemide 917 
in pharmaceutical dosage form. IJRAP. 2010;1(2):459-67. 918 
69. Armand M, Hamosh M, Mehta NR, Angelus PA, Philpott JR, Henderson TR, et al. Effect of human 919 
milk or formula on gastric function and fat digestion in the premature infant. Pediatric research. 1996 920 
Sep;40(3):429-37. 921 
70. Armand M, Hamosh M, DiPalma JS, Gallagher J, Benjamin SB, Philpott JR, et al. Dietary fat 922 
modulates gastric lipase activity in healthy humans. The American journal of clinical nutrition. 1995 923 
Jul;62(1):74-80. 924 
71. Avery GB, Randolph JG, Weaver T. Gastric acidity in the first day of life. Pediatrics. 1966 925 
Jun;37(6):1005-7. 926 
38 
 
72. Cote CJ, Goudsouzian NG, Liu LM, Dedrick DF, Szyfelbein SK. Assessment of risk factors related to 927 
the acid aspiration syndrome in pediatric patients-gastric ph and residual volume. Anesthesiology. 1982 928 
Jan;56(1):70-2. 929 
73. Datta S, Houle GL, Fox GS. Concentration of lidocaine hydrochloride in newborn gastric fluid after 930 
elective caesarean section and vaginal delivery with epidural analgesia. Canadian Anaesthetists' Society 931 
journal. 1975 Jan;22(1):79-83. 932 
74. Ebers DW, Gibbs GE, Smith DI. Gastric acidity on the first day of life. Pediatrics. 1956 933 
Nov;18(5):800-2. 934 
75. Euler AR, Byrne WJ, Meis PJ, Leake RD, Ament ME. Basal and pentagastrin-stimulated acid 935 
secretion in newborn human infants. Pediatric research. 1979 Jan;13(1):36-7. 936 
76. Goresky GV, Finley GA, Bissonnette B, Shaffer EA. Efficacy, duration, and absorption of a paediatric 937 
oral liquid preparation of ranitidine hydrochloride. Canadian journal of anaesthesia = Journal canadien 938 
d'anesthesie. 1992 Oct;39(8):791-8. 939 
77. Griswold CC, Shohl AT. GAstric digestion in new-born infants. American Journal of Diseases of 940 
Children. 1925;30(4):541-9. 941 
78. Jahr JS, Burckart G, Smith SS, Shapiro J, Cook DR. Effects of famotidine on gastric pH and residual 942 
volume in pediatric surgery. Acta anaesthesiologica Scandinavica. 1991 Jul;35(5):457-60. 943 
79. Maekawa N, Mikawa K, Yaku H, Nishina K, Obara H. Effects of 2-, 4- and 12-hour fasting intervals 944 
on preoperative gastric fluid pH and volume, and plasma glucose and lipid homeostasis in children. Acta 945 
anaesthesiologica Scandinavica. 1993 Nov;37(8):783-7. 946 
80. Maffei HV, Nobrega FJ. Gastric pH and microflora of normal and diarrhoeic infants. Gut. 1975 947 
Sep;16(9):719-26. 948 
81. Meakin G, Dingwall AE, Addison GM. Effects of fasting and oral premedication on the pH and 949 
volume of gastric aspirate in children. British journal of anaesthesia. 1987 Jun;59(6):678-82. 950 
82. Miclat NN, Hodgkinson R, Marx GF. Neonatal gastric pH. Anesthesia and analgesia. 1978 Jan-951 
Feb;57(1):98-101. 952 
83. Mikawa K, Nishina K, Maekawa N, Asano M, Obara H. Lansoprazole reduces preoperative gastric 953 
fluid acidity and volume in children. Canadian journal of anaesthesia = Journal canadien d'anesthesie. 954 
1995 Jun;42(6):467-72. 955 
84. Nishina K, Mikawa K, Maekawa N, Tamada M, Obara H. Omeprazole reduces preoperative gastric 956 
fluid acidity and volume in children. Canadian journal of anaesthesia = Journal canadien d'anesthesie. 957 
1994 Oct;41(10):925-9. 958 
85. Omari TI, Davidson GP. Multipoint measurement of intragastric pH in healthy preterm infants. 959 
Archives of disease in childhood Fetal and neonatal edition. 2003 Nov;88(6):F517-20. 960 
86. Rogers IM, Drainer IK, Moore MR, Buchanan KD. Plasma gastrin in congenitial hypertrophic pyloric 961 
stenosis. A hypothesis disproved. Archives of disease in childhood. 1975 Jun;50(6):467-71. 962 
87. Sandhar BK, Goresky GV, Maltby JR, Shaffer EA. Effect of oral liquids and ranitidine on gastric fluid 963 
volume and pH in children undergoing outpatient surgery. Anesthesiology. 1989 Sep;71(3):327-30. 964 
88. Splinter WM, Stewart JA, Muir JG. Large volumes of apple juice preoperatively do not affect gastric 965 
pH and volume in children. Canadian journal of anaesthesia = Journal canadien d'anesthesie. 1990 966 
Jan;37(1):36-9. 967 
89. Fallingborg J, Christensen LA, Ingeman-Nielsen M, Jacobsen BA, Abildgaard K, Rasmussen HH, et 968 
al. Measurement of gastrointestinal pH and regional transit times in normal children. 969 
JPediatrGastroenterolNutr. 1990 8/1990;11(2):211-4. 970 
90. Fredrikzon B, Olivecrona T. Decrease of lipase and esterase activities in intestinal contents of 971 
newborn infants during test meals. Pediatric research. 1978 May;12(5):631-4. 972 
39 
 
91. Gilbertson HR, Rogers EJ, Ukoumunne OC. Determination of a practical pH cutoff level for reliable 973 
confirmation of nasogastric tube placement. JPEN Journal of parenteral and enteral nutrition. 2011 974 
Jul;35(4):540-4. 975 
92. Metheny NA, Eikov R, Rountree V, Lengettie E. Clinical Research: Indicators of Feeding-Tube 976 
Placement in Neonates. Nutrition in Clinical Practice. 1999 December 1, 1999;14(6):307-14. 977 
93. Boehm G, Bierbach U, Senger H, Jakobsson I, Minoli I, Moro G, et al. Activities of lipase and trypsin 978 
in duodenal juice of infants small for gestational age. J Pediatr Gastroenterol Nutr. 1991 Apr;12(3):324-7. 979 
94. Boehm G, Braun W, Moro G, Minoli I. Bile acid concentrations in serum and duodenal aspirates of 980 
healthy preterm infants: effects of gestational and postnatal age. Biology of the neonate. 1997;71(4):207-981 
14. 982 
95. Brueton MJ, Berger HM, Brown GA, Ablitt L, Iyngkaran N, Wharton BA. Duodenal bile acid 983 
conjugation patterns and dietary sulphur amino acids in the newborn. Gut. 1978 Feb;19(2):95-8. 984 
96. Challacombe DN, Edkins S, Brown GA. Duodenal bile acids in infancy. Archives of disease in 985 
childhood. 1975 Nov;50(11):837-43. 986 
97. Encrantz JC, Sjovall J. On the bile acids in duodenal contents of infants and children. Bile acids and 987 
steroids 72. Clinica chimica acta; international journal of clinical chemistry. 1959 Nov;4:793-9. 988 
98. Glasgow JF, Dinsmore H, Molla A, Macfarlane T. A comprehensive study of duodenal bile salts in 989 
newborn infants and their relationship to fat absorption. Irish journal of medical science. 1980 990 
Sep;149(9):346-56. 991 
99. Norman A, Strandvik B, Ojamae O. Bile acids and pancreatic enzymes during absorption in the 992 
newborn. Acta paediatrica Scandinavica. 1972 Sep;61(5):571-6. 993 
100. Poley JR, Dower JC, Owen CA, Jr., Stickler GB. Bile Acids in Infants and Children. The Journal of 994 
laboratory and clinical medicine. 1964 May;63:838-46. 995 
101. Lavy U, Silverberg M, Davidson M. Role of bile acids in fat absorption in low birth weights infants. 996 
Pediatric research. 1971 08//print;5(8):387-. 997 
102. Barbero GJ, Runge G, Fischer D, Crawford MN, Torres FE, Gyorgy P. Investigations on the bacterial 998 
flora, pH, and sugar content in the intestinal tract of infants. The Journal of pediatrics. 1952 Feb;40(2):152-999 
63. 1000 
103. Boehm G, Bierbach U, Senger H, Jakobsson I, Minoli I, Moro G, et al. Postnatal adaptation of lipase- 1001 
and trypsin-activities in duodenal juice of premature infants appropriate for gestational age. Biomedica 1002 
biochimica acta. 1990;49(5):369-73. 1003 
104. Robinson PJ, Smith AL, Sly PD. Duodenal pH in cystic fibrosis and its relationship to fat 1004 
malabsorption. Digestive diseases and sciences. 1990 Oct;35(10):1299-304. 1005 
105. Rune SJ, Viskum K. Duodenal pH values in normal controls and in patients with duodenal ulcer. 1006 
Gut. 1969 Jul;10(7):569-71. 1007 
106. Challacombe DN, Brown GA, Edkins S. Duodenal bile acids in infants with protracted diarrhoea. 1008 
Archives of disease in childhood. 1979 Feb;54(2):131-4. 1009 
107. Harries JT, Muller DP, McCollum JP, Lipson A, Roma E, Norman AP. Intestinal bile salts in cystic 1010 
fibrosis: studies in the patient and experimental animal. Archives of disease in childhood. 1979 1011 
Jan;54(1):19-24. 1012 
108. Armand M, Borel P, Pasquier B, Dubois C, Senft M, Andre M, et al. Physicochemical characteristics 1013 
of emulsions during fat digestion in human stomach and duodenum. The American journal of physiology. 1014 
1996 Jul;271(1 Pt 1):G172-83. 1015 
109. Hernell O, Staggers JE, Carey MC. Physical-chemical behavior of dietary and biliary lipids during 1016 
intestinal digestion and absorption. 2. Phase analysis and aggregation states of luminal lipids during 1017 
duodenal fat digestion in healthy adult human beings. Biochemistry. 1990 Feb 27;29(8):2041-56. 1018 
 1019 
40 
 
 1020 
Table I: Composition of adult biorelevant media  1021 
 1022 
*adult media compositions as described in Jantratid et al. (2) 1023 
 1024 
Component FaSSGF FeSSGF FaSSIF.v2 FeSSIF.v2 
Sodium Taurocholate  80 (uM) - 3 (mM) 10 (mM) 
Lecithin 20 (uM) - 0.2 (mM) 2 (mM) 
Pepsin (mg/mL) 0.1 - - - 
Sodium Chloride 
(mM) 
34.2 237.02 68.62 125.5 
Acetic Acid (mM) - 17.12 - - 
Sodium Acetate (mM) - 29.75 - - 
Maleic Acid (mM) - - 19.12 55.02 
Sodium Hydroxide 
(mM) 
- - 34.8 81.65 
Glyceryl Monooleate 
(mM) 
- - - 5 
Sodium Oleate (mM) - - - 0.8 
Milk:Buffer - 1:1  - 
HCl/NaOH qs pH 1.6 pH 5 pH 6.5 pH 5.8 
     
pH 1.6 5 6.5 5.8 
Osmolarity 
(mOsm/kg) 
120.7 400 180 390 
Buffering Capacity 
(mEq/L/ ∆pH) 
- 25 10 25 
41 
 
Table II: Compound physicochemical properties  1025 
 1026 
 1027 
 1028 
 1029 
*physicochemical data obtained from DrugBank (61) 1030 
  1031 
Compound Molecular Weight 
(g/mol) 
LogP pKa (acid/base) 
Dapsone 248 0.97 2.4 (base) 
Griseofulvin 353 2.18 - 
Carbamazepine 236 2.45 -  
Phenytoin 252 2.47 9.5 (acid) 
Spironolactone 417 2.78 -  
Indomethacin 358 4.27 3.8 (acid) 
Fenofibrate 361 5.3 -  
42 
 
 1032 
Table III: HPLC-UV analytic conditions 1033 
Column Compound Mobile Qa 
(ml/
min) 
Temp 
(0C) 
Inj 
Vol 
(μL) 
 λb 
(nm) 
Rtc 
(min) 
Reference 
1 Carbamazepine MeOH/ Water (60:40) 1 20 50 285 6.6 (62) 
2 Dapsone Water with ammonium 
acetate 0.0286M / MeOH 
(70:30) 
1 20 10 295 5.6 (63) 
2 Fenofibrate MeOH/ Acetate buffer 
0.010M pH=3.7 (82:18) 
1 25 80 286 6.5 (64) 
2 Griseofulvin MeOH/ Water (65:35) 1 20 20 292 4.5 (65) 
2 Indomethacin MeOH/ Water with 1.67% 
orthophosphoric acid 
(70:30) 
1 23 100 270 9.9 (66) 
2 Phenytoin* Water/ AcN (50:50) 0.5 20 10 210 5.6 (67) 
2 Spironolactone MeOH/ Water (70:30) 1 20 40 237 5.7 (68) 
 1034 
Column 1: Hypersil (Thermo) BDS -C18 250 x 4.6mm - 5 μm 1035 
Column 2: Zorbax SB-C18 150 x 4.6mm – 3.5μm 1036 
a - Q = flow rate  1037 
b - λ = UV wavelength 1038 
c - Rt = retention time 1039 
* - HPLC conditions altered for solubility assessments with FeSSGF media due to interference with media 1040 
components. Mobile phase (Water/AcN – 60:40), Q (1ml/min) and Rt=4.8 mins.  1041 
 1042 
 1043 
 1044 
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Table IV: Pediatric Fasted-State Simulated Gastric Fluids (P-FaSSGF) 1045 
Component Pn-FaSSGFa Pi-FaSSGFb 
Sodium Taurocholate (uM) 20 60 
Lecithin (uM) 5 15 
Pepsin (mg/mL) 0.015 0.025 
 Sodium Chloride (mM) 34.2 34.2  
HCl qs pH 1.6 pH 1.6 
   
pH 1.6 1.6 
Osmolarity (mOsm/kg) 120.7 120.7  
Buffering Capacity (mEq/L/ ∆pH) - - 
 1046 
(a) Pn-FaSSGF – pediatric fasted-state gastric media representative of neonates (0-28 days) 1047 
(b) Pi-FaSSGF – pediatric fasted-state gastric media representative of infants (1-12 months)  1048 
 1049 
  1050 
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Table V: Predictive performance of the osmolality regression equation 1051 
Feed Osmolality (Median 
- mOsm/kg)a 
 
Measured Gastric 
Osmolality - 60 min 
postprandial (Median - 
mOsm/kg)a 
Predicted Gastric 
Osmolality – 60 min 
postprandial 
(mOsm/kg)b 
% Prediction Error 
((Pred– Obs) / Obs) x 100 
344 354 327 -7.6 % 
426 383 368 -3.9 % 
315 315 313 -0.6 % 
 1052 
(a) Values derived from Thatrimontrichai and Janjindamai (37)  1053 
(b) Predictions based on regression model, as derived from Billeaud et al. (36) 1054 
 1055 
  1056 
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Table VI: Pediatric Fed-State Simulated Gastric Fluids (P-FeSSGF) 1057 
Component Pnc-FeSSGFa Pns-FeSSGFb 
 Sodium Chloride (mM) 100.35 94.79 
Acetic Acid (mM) 7.25 7.25 
Sodium Acetate (mM) 64.65 64.65 
Milk:buffer 1:1 1:1 
HCl/NaOH qs pH 5.7 pH 5.7 
   
pH 5.7 
 
5.7 
Osmolarity (mOsm/kg) 340 240 
Buffering Capacity (mEq/L/ ∆pH) 15  15 
 1058 
(a) Pnc-FeSSGF – pediatric fed-state gastric media representative of neonates (0-28 days) fed cow’s 1059 
milk-based formula 1060 
(b) Pns-FeSSGF – pediatric fed-state gastric media representative of neonates (0-28 days) fed soy-1061 
based formula  1062 
 1063 
  1064 
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Table VII: Pediatric Fasted-State Simulated Intestinal Fluids (P-FaSSIF) 1065 
Component P-FaSSIF-50%a P-FaSSIF-150%b 
Sodium Taurocholate (mM) 1.5 4.5 
Lecithin (mM) 0.1 0.3 
Maleic acid (mM) 19.12 19.12 
Sodium hydroxide (mM) 34.8 34.8 
Sodium Chloride (mM) 68.62  68.62  
   
pH 6.5 6.5 
Osmolarity (mOsm/kg) 180 180 
Buffering Capacity (mEql/L/ ∆pH)  10 10 
 1066 
(a) P-FaSSIF-50% – pediatric fasted-state intestinal media formulated with bile salt concentrations 1067 
50% (i.e. 1.5mM) of adult levels 1068 
(b) P-FaSSIF-150% – pediatric fasted-state intestinal media formulated with bile salt concentrations 1069 
150% (i.e. 4.5 mM) of adult levels 1070 
 1071 
  1072 
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Table VIII: Pediatric Fed-State Simulated Intestinal Fluids (P-FeSSIF) 1073 
Component Pnb-FeSSIFa Pnc-FeSSIFb Pi-FeSSIFc 
Sodium Taurocholate (mM) 2.5 2.5 7.5 
Lecithin (mM) 0.5 0.5 1.5 
Glyceryl monooleate (mM) 5 6.65 5 
Sodium oleate (mM) 0.8 1.06 0.8 
Maleic acid (mM) 55.02 55.02 55.02 
Sodium hydroxide (mM) 81.65 81.65 81.65 
 Sodium Chloride (mM) 95 111.73 107.35 
    
pH 5.8 5.8 5.8 
Osmolarity (mOsm/kg) 300  330  330  
Buffering Capacity 
(mEq/L/ ∆pH)  
25 25 25 
 1074 
(a) Pnb-FeSSIF – pediatric fed-state intestinal media representative of neonates (0-28 days) fed breast 1075 
milk 1076 
(b) Pnc-FeSSIF – pediatric fed-state intestinal media representative of neonates (0-28 days) fed cow’s 1077 
milk-based formula 1078 
(c) Pi-FeSSIF – pediatric fed-state intestinal media representative of infants (1-12 months)  fed cow’s 1079 
milk-based formula 1080 
 1081 
  1082 
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Table IX: Predictive performance of Mithani et al.’s (17) equations at characterizing compound specific 1083 
solubility changes in pediatric media 1084 
Compound RMSEa 
Dapsone (logP = 0.97) 8.5% 
Griseofulvin (logP = 2.18) 3.7% 
Carbamazepine (logP = 2.45) 16.9% 
Phenytoin (logP = 2.47) 10.9% 
Spironolactone (logP = 2.78) 17.4% 
Indomethacin (logP = 4.27) 39.1% 
Fenofibrate (logP = 5.3) 28.5% 
 1085 
(a) Root mean square error (RMSE) was tabulated based on Eq 4. Only pediatric media formulated 1086 
with bile salts (i.e. P-FaSSGF, P-FaSSIF, and P-FeSSIF) were included in the assessment. 1087 
 1088 
  1089 
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 1090 
Figure 1: (A) Fasting gastric pepsin concentrations amongst pediatrics (21, 22, 25, 69) is expressed as a 1091 
percentage of adult values (23, 25, 70). Investigations where pepsin concentrations were quantified over 1092 
a specific age range without denoting the group’s mean age were graphically depicted as the middle of 1093 
the age range. Average (mean) values pertaining to neonates (0-28days) and infants (1m-12m) are 1094 
illustrated for reference (red – x’s). (B) Fasting gastric pH amongst pediatrics (black circles) is depicted as 1095 
the central tendency, either mean or median, from separate investigations (18-20, 27, 38, 71-88). Studies 1096 
where gastric pH values was quantified over specific age range without denoting the group’s mean age 1097 
were graphically depicted using the middle of the age range. Adult data is depicted by mean pH values 1098 
from separate studies, as summarized by Di Maio and Carrier (26). Dashed reference lines correspond to 1099 
the maximum and minimum mean pH values observed within the presented adult studies. 1100 
 1101 
  1102 
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 1103 
Figure 2: Neonatal gastric osmolality 60 minutes post-meal expressed as a function of feed osmolality. 1104 
Data (black circles) represent average gastric osmolality values recorded amongst neonatal subjects as 1105 
described by Billeaud et al (36).  A linear regression model (red line) was fit to the data. 1106 
  1107 
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 1108 
Figure 3: (A) Pediatric fasting intestinal pH (black circles) is depicted as the central tendency, either 1109 
mean or median, from separate investigations (20-22, 89-92). Studies where pH was summarized over a 1110 
specific age range without denoting the group’s mean age were graphically depicted using the middle of 1111 
the age range. The majority of data was derived from distal duodenum, though studies which included 1112 
sampling sites from the proximal jejunum were also included. Adult duodenal bile acid concentrations 1113 
(red circles) are depicted as mean values from separate studies, as summarized by Fuchs and Dressman 1114 
(39). (B) Fasting duodenal bile salt concentrations amongst pediatrics (black circles) are depicted as the 1115 
central tendency, either mean or median, from separate investigations (43, 44, 93-101). Studies where 1116 
bile acids were summarized over a specific age range without denoting the group’s mean age were 1117 
graphically depicted using the middle of the age range. Adult duodenal bile acid concentrations (red 1118 
circles) are depicted as mean values from separate studies, as summarized by Fuchs and Dressman (39). 1119 
  1120 
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 1121 
Figure 4: (A) Fed-state duodenal pH from separate pediatric investigations (black circles) is depicted by 1122 
the central tendency, either mean or median (90, 102-104). Studies where pH was summarized over a 1123 
specific age range without denoting the group’s mean age were graphically depicted using the middle of 1124 
the age range. Adult pH values (red circles) are presented as the central tendency (mean or median) 1125 
from separate investigations (33, 34, 40, 90, 105). (B) Neonatal duodenal osmolality 60 minutes post-1126 
meal expressed as a function of feed osmolality. Data (black circles) represent average duodenal 1127 
53 
 
osmolality values recorded amongst neonatal subjects as described by Billeaud et al (36). A linear 1128 
regression model (red line) was fit to the data. (C) Fed-state duodenal bile salt concentrations amongst 1129 
pediatrics (black circles) is depicted as the mean from separate investigations (44, 96, 98, 99, 103, 106, 1130 
107). Studies where data was summarized over a specific age range without denoting the group’s mean 1131 
age were graphically depicted using the middle of the age range. Adult duodenal bile acid 1132 
concentrations (0.5-1hr postprandially) (red circles) are depicted as the mean value from the various 1133 
publications (26, 33, 40, 108, 109). 1134 
 1135 
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Figure 5: Measured solubility in age-specific biorelevant media expressed as the mean solubility ratio 1138 
(bars) between each respective pediatric and adult media (i.e. Pi-FaSSGF / FaSSGFAdult).  Predicted 1139 
solubility ratios due to differences in media bile acid content were calculated for P-FaSSGF, P-FaSSIF, and 1140 
P-FeSSIF according Mithani et al.’s equations (red line, dots) (17). Dashed lines (---) characterizing the 1141 
bioequivalence criterion (80-125%) are displayed for reference. Media are denoted as follows: Pi-FaSSGF 1142 
(Infant FaSSGF), Pn-FaSSGF (Neonate FaSSGF), Pnc-FeSSGF (Neonate FeSSGF comprised of cow’s milk-1143 
based formula), Pns-FeSSGF (Neonate FeSSGF comprised of soy-based formula), P-FaSSIF-150% (Pediatric 1144 
FaSSIF comprised with 4.5 mM NaTc), P-FaSSIF-50% (Pediatric FaSSIF comprised with 1.5 mM NaTc), Pi-1145 
FeSSIF (Infant FeSSIF), Pnb-FeSSIF (Neonatal breast-fed FeSSIF), and Pnc-FeSSIF (Neonatal formula-fed 1146 
FeSSIF). Statistically significant solubility differences (p≤0.05) compared to (a) adult media, (i) infant 1147 
media, (n) neonatal media, and (b) P-FaSSIF-150% were depicted using the symbols indicated. 1148 
 1149 
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 1151 
Figure 6: Measured solubility in age-specific biorelevant media expressed as the mean solubility ratio 1152 
(bars) between each respective pediatric and adult media (i.e. Pi-FaSSGF / FaSSGFAdult).  Predicted 1153 
solubility ratios due to differences in media bile acid content were calculated for P-FaSSGF, P-FaSSIF, and 1154 
P-FeSSIF according Mithani et al.’s equations (red line, dots) (17). Dashed lines (---) characterizing the 1155 
bioequivalence criterion (80-125%) are displayed for reference.  For a description of media abbreviations 1156 
and symbols (a,b,n,i), see the footnote to Figure 5. 1157 
 1158 
 1159 
